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Chapter 1
General introduction




Pharmacological research in pediatrics
More than 100 years ago the founding father of pediatrics in the United States of America, 
Dr. Abraham Jacobi, stated “Pediatrics does not deal with miniature men and women, with 
reduced doses and the same class of disease in smaller bodies, but has its own independent 
range and horizon”.1 With this statement the need for age-appropriate pharmacological 
research for children was already emphasized more than a century ago. Several physical 
aspects with a great influence on distribution and metabolism of drugs change in growing 
children, such as body composition, motility and pH of the gastro-intestinal tract, perfusion 
of skeletal muscles, composition of plasma proteins, concentration of CYP-enzymes, 
glomerular filtration rate etcetera. As this large amount of factors change disproportional, 
dosing formulas to determine age-specific doses are almost totally unusable, especially for 
children younger than 8 years.2 Despite this important argument to develop age-appropriate 
pharmacological research in children, this kind of research is still limited, particularly in 
the field of Neonatology. The relatively small pediatric and neonatal population and the 
need for testing drugs extensively for different age categories make research in children 
very expensive and therefore less attractive for the pharmaceutical industry. In addition, 
national law rules, ethical questions and the need for parental consent are other major 
problems for developing ethical justified clinical trials in children. A direct consequence 
of the lack of pharmacological research in children is a high amount of unlicensed (not 
registered in the Netherlands or modified formulations of registered drugs) and off-label 
(not registered for the used dosage, age, indication and/or route of administration) drug 
prescriptions.3,4 These unlicensed and off-label prescriptions are most common in very ill 
children, especially those admitted on the neonatal intensive care unit (NICU). At least 
one off-label or unlicensed drug is prescribed to 80-93% of the NICU population.3 The 
main reason for being off-label is the lack of age specific dosage regimes. Concerning the 
prescription of unlicensed and/or off-label drugs, we must consider if we want to deprive 
children of potential therapeutic benefits of unlicensed drugs instead of exposing them 
to possible unknown adverse effects.3 This is a difficult consideration as several clinical 
conditions could not be treated without unlicensed and off-label prescriptions. Otherwise 
is usage of unlicensed and off-label drugs associated with an increased risk for adverse 
effects, urging for careful usage.4,5
Until when pharmacological trials in pediatrics become more extensive, pediatricians will 
have to deal with the limited availability of licensed and on-label drugs and work with 
alternative sources of evidence concerning safety and efficacy of medicine usage in children.





The most appropriate alternative design to evaluate safety and efficacy of medication use in 
children is a retrospective study. The lack of acquiring reliable evidence from retrospective 
studies is a common heard argument against this design, as it has a low ranking in the 
pyramid of evidence. However, an example of a pioneering discovery detected with a 
case-control study, was the finding of the relationship between smoking and lung cancer, 
confirming the usefulness of retrospective study design.6
When prospective evidence is not available, retrospective studies can be very valuable for 
evaluation of medical policies. Unlicensed and/or off-label drugs can be analyzed using 
a cohort of children over a fixed (passed) time period, which received a particular drug. 
Analysis of baseline characteristics of the population and details about achieving treatment 
goal, dosage, duration of administration and possible adverse effects, can demonstrate the 
advantages and disadvantages of the drug, so usage can be fine-tuned.
In addition to unlicensed drugs, the usage of licensed drugs also needs to be evaluated 
and fine-tuned on a regular basis. When a specific treatment protocol is started after a 
time-consuming process, it is often considered to be effective and safe enough to be used 
extensively. However, diversity of diseases, comorbidity and treatment possibilities may 
change during time. Frequent re-assessments of current management guidelines are thus 
of paramount importance including evaluation of their efficacy and safety. Nevertheless, 
evaluations of current management protocols are not frequently performed, since it is 
probably more “rewarding” or “exiting” to invent completely new treatment strategies. 
Based on these evaluations, the incidence and associated comorbidity among current 
policies can be surveyed and compared with other centers and populations (benchmarking). 
Unexpected outcomes may provide new insights and can be used as guidance for protocol 
adjustments or provide a basis for new randomized controlled trials. In many cases, these 
randomized controlled trials are only ethically justified when the advantages of possible 
new interventions are supported by strong evidence from retrospective cohort studies.
Another great benefit of retrospective studies is that they offer the opportunity to investigate 
relatively rare diseases, a common problem in the field of Neonatology. In these situations 
sample sizes are often small and prospective investigation of a large enough number of cases 
for reliable statistical analysis is sometimes very difficult if not impossible. 
Although randomized controlled trials continue to provide the best evidence to 
guide clinical treatment and retrospective cohort studies may suffer from a various 
methodological limitations, especially errors due to confounding and bias, the latter 
play an important role in the evaluation of clinical treatment protocols and continue 
to be essential in medical research.




In this thesis we present six clinical studies, six ‘Neonatal pearls’ reflecting our current 
neonatal practice (using licensed as well as unlicensed medicines). Although topics 
may seem very diverse at first sight, the common denominator is the evaluation of 
management guidelines with focus on effectiveness and risk of a particular drug. The 
problems chosen to investigate are all based on important practical questions with 
clinical relevance. All described clinical conditions are severe but rare, which results 
in restricted availability of literature. Our aim is to provide additional evidence with 
recommendations, directly usable in clinical practice. Due to the lack of literature 
and the small sample sizes, both caused by the rarity of the studied conditions, a 
retrospective cohort study was the only appropriate design to evaluate efficacy, safety 
and/or long term outcome of the current protocols. These six ‘Neonatal Pearls’ can 
serve as potential foundations for adjustment of clinical protocols and guidance on 
future prospective studies and randomized controlled trials.
Outline of the thesis
The general aim of this thesis was to emphasize the importance of retrospective research 
in Neonatology and the necessity of regular and careful evaluation of already existing 
treatment policies. We describe six retrospective studies investigating effectiveness, 
safety and/or long term consequences of various drugs used in neonates.
Chapter 1 provides background information on the choice of the various conditions 
reported in chapters 2 to 7 and the choice of retrospective cohort studies. 
Chapter 2 investigates fetal, neonatal and developmental outcome of children exposed 
to maternal lithium use during intrauterine life to gain more knowledge about the 
safety of lithium use during pregnancy. Lithium is the main treatment for women with 
a bipolar disorder; discontinuation of lithium during pregnancy increases the risk of 
relapse postpartum. Follow-up was collected prospectively with assessment of growth, 
neurological examination, cognitive and behavioral assessments. 
In Chapter 3, we evaluated the efficacy and safety of antenatal treatment of fetal 
and neonatal allo-immune thrombocytopenia (FNAIT) with weekly maternal IVIG 
and postnatal matched platelet transfusions (if necessary). Important outcomes were 
the occurrence of intracranial hemorrhage (ICH), petechiae, hematomas and severe 
neonatal thrombocytopenia. The postnatal course of neonatal platelet counts was 




followed and graphically analyzed.
Chapter 4 investigates the efficacy of repeated courses of ibuprofen for closure of a 
patent ductus arteriosus (PDA). Ibuprofen is the first treatment of choice for PDA 
in preterm infants; in most centers failure of a second course is followed by surgical 
closure. Recent studies suggest that surgical intervention is associated with adverse 
outcome. The closure rate and safety of a second and third course of ibuprofen in 
preterm infants was retrospectively evaluated, in order to postpone surgical closure. 
Risk factors for failure of PDA closure and its clinical consequences were also studied.
Chapter 5 evaluates the combination therapy with rifampin and vancomycin in 
persistent Coagulase Negative Staphylococcal (CNS) sepsis in neonates. Infection 
parameters, such as C-reactive protein (CRP) levels before and after start of rifampin 
therapy, and peak and trough serum levels of vancomycin before the start of rifampin 
therapy were analyzed for efficacy of this treatment regimen. 
In Chapter 6 we analyzed the outcome of infants of mothers with idiopathic 
thrombocytopenic purpura (ITP) during pregnancy by scoring the occurrence of 
intracranial hemorrhage (ICH) and graphical analysis of the postnatal course of 
neonatal platelet counts. Effectiveness and safety of various postnatal treatment 
strategies, such as platelet transfusions, IVIG and/or prednisone were evaluated.
Chapter 7 describes a retrospective follow-up study to determine the long term effects 
of insulin treatment for hyperglycemia on growth and neurodevelopmental outcome 
of preterm infants. Outcome at two years of age of preterm infants with hyperglycemia 
and controls, matched for gestational age and birth weight, were compared to estimate 
the efficacy and safety of insulin therapy for hyperglycemia.
Chapter 8 – In the general discussion the main results of this thesis will be discussed 
from a broader perspective, focusing on future perspectives. The discussion will end 
with a short main conclusion, reflecting on the points emphasized in the general 
introduction.
Chapter 9 – Summary of this thesis.
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Chapter 2
Fetal, neonatal and 
developmental outcomes of 
lithium-exposed pregnancies
N.M. van der Lugt*, J.S. van de Maat*, I.L. van Kamp, E.A. Knoppert-van der 
Klein, J.G. Hovens, F.J. Walther. *Both authors contributed equally
Early Human Development 2012;88:375-78.





Many women with a bipolar disorder are of reproductive age and will need to continue 
lithium treatment during pregnancy. The teratogenic and perinatal effects of lithium are 
known, but not the long-term effects of lithium on neurodevelopment of the children. 
This study investigates growth, neurological, cognitive and behavioral development of 
children exposed to lithium in utero.
Methods
In an observational retrospective cohort study 15 children who were exposed to lithium 
in utero were investigated at 3–15 years of age. Neurological development was tested 
using the Hempel or Touwen examination. Cognitive development was assessed with 
the Bayley Scales of Infant Development III, Wechsler Preschool and Primary Scale 
of Intelligence or the Wechsler Intelligence Scale for Children. Parents completed the 
Child Behavior Checklist to assess behavioral development and a standard questionnaire 
about general development of the child since birth.
Results
One child had signs of a minor neurological dysfunction, but without further clinical 
implications. The results of the cognitive tests were within normal limits, although 
most children had lower scores on the performance IQ subtest. Growth, behavior and 
general development were within the normal range. 
Conclusion
Continuing lithium therapy during pregnancy did not cause adverse effects on growth, 
neurological, cognitive and behavioral development of exposed children.





Since the 1950s lithium is the most important drug in the pharmacological treatment 
of bipolar disorder. Bipolar disorder is common in women in their reproductive 
age, which raises the question whether intrauterine exposure to lithium affects 
neurodevelopmental outcome of exposed children.1 Discontinuation of lithium use 
during pregnancy is contraindicated as this is associated with a twofold greater risk of 
recurrence of a new episode of mania or depression.2,3,4
Lithium entirely readily crosses the placenta and the fetus receives 100% of the drug 
during pregnancy. High serum lithium levels at delivery are associated with a higher 
incidence of neonatal complications and have led to interruption of lithium therapy 
or use of lower doses of lithium shortly before delivery.5
The risk of congenital disorders of children who received lithium in utero has been 
extensively investigated. A retrospective analysis of data from the Danish Register 
of Lithium Babies in 1976 suggested a high risk of Ebstein’s anomaly (6 out of 225 
exposed children versus an incidence of 1 in 20,000 in the general population)6, 
but this turned out to be a gross overestimation due to a voluntary reporting bias. 
The Motherisk Program performed two studies on the potential teratogenic effect of 
lithium and found a relative risk for all congenital disorders of 1.2 and for cardiac 
disorders of 1.1 and no association of lithium use with Ebstein’s anomaly.7,8 A review 
of the epidemiologic data by Cohen et al. concluded that the teratogenic risk of first-
trimester lithium exposure is lower than previously suggested.9
Many case reports describe neonatal lithium toxicity which often presents as a 
“floppy infant syndrome” characterized by lethargy, poor sucking, tachypnea, 
tachycardia, respiratory distress syndrome, cyanosis and hypotonie.10 Other neonatal 
problems include structural and functional cardiovascular problems, macrosomia, 
hyperbilirubinemia, diabetes insipidus, and hypothyreoidism.10 However, an elevated 
risk of these adaptation problems and complications has never been significantly 
proven and most of them are transient and without long-term consequences.11
Although lithium does not seem to cause major congenital disorders, there is a realistic 
possibility of long-term effects on the developing fetal brain during pregnancy.12,13 The 
first trimester is the most critical period for drug-induced disorders, but the brain is 
developing throughout pregnancy and highly vulnerable to the latent cognitive and 
neurological impact of drugs.14 Youngs et al. investigated long-term effects of lithium 
on the developing rat brain and found long-lasting increases in anxiety-like behavior.15 
Except for a follow-up questionnaire reported by Schou, long-term effects of exposure 
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to lithium in utero have not been studied in humans.16,17 This lack of knowledge causes 
fear in women who use lithium and are pregnant, or are planning a pregnancy.18
The objective of this study was to investigate growth and neurological, cognitive and 
behavioral development of children who were exposed to lithium in utero. 
Methods
Participants
The Perinatal Center of the Leiden University Medical Center (LUMC) prospectively 
collected perinatal data on all mothers treated with lithium (target maintenance 
serum lithium levels 0.6–0.8 mmol/L) for bipolar disorder during pregnancy and 
their children in the period between 1-1-1994 and 31-12-2007. Mothers with a 
bipolar disorder without lithium therapy were not identified in the defined period. 
Twenty-one mothers of 30 children born alive in the LUMC between 1-1-1994 
and 31-12-2007 were asked by their psychiatrist or obstetrician for permission 
to examine their children for follow-up purposes. The psychiatrist or obstetrician 
called the mothers to inform them about the study and ask them if they wanted to 
participate. If they agreed, information about the study and follow-up questionnaires 
were sent and the physical and psychological examination scheduled. The ethics 
committee of the hospital approved the study and informed consent was obtained 
from the parents. 
Study design
Growth and neurological, cognitive and behavioral outcome of lithium-exposed 
children were assessed using standard tests, validated in the Dutch population. Data 
collection was done during the neonatal period and between November 2008 and 
December 2009. The visit of the children with one of their parents to the hospital 
lasted about 4 hours.
Assessments
Neonatal assessment
The neonatal database provided 1. data on the medical and obstetric history of the 
mothers, including use of medications during pregnancy, serum lithium values, 
method of delivery, and perinatal complications, and 2. data collected during the 24 
hour observation of each child after birth, including birth weight; 1 and 5 min Apgar 




scores; umbilical cord blood lithium levels; chest X-ray, ECG, and echocardiography 
(if indicated); blood glucose, serum electrolytes, and thyroid function. 
Developmental assessment and growth
Physical and mental development of the child was screened using a questionnaire to 
be filled in by the mother. Items that were asked were growth, illnesses, behavioral 
problems, motor problems and developmental milestones. Growth of the children 
was assessed by measurement of height, weight and head circumference and plotted 
in the Dutch growth curves.
Neurological examination
Children between 2 and 5 years of age were assessed according to the Hempel 
examination.19 Outcome of this test is divided into 3 groups: normal, simple minor 
neurological dysfunction (MND) when dysfunction is detected in 1 cluster, and 
complex MND when dysfunction is found in more than 1 cluster. For older children 
the Touwen protocol for neurological examination was used.20,21 Outcome for that 
test is 0 (normal), 1 (simple MND), 2 (complex MND), 3 (Complex Pathology, CP). 
Cognitive testing 
Cognition was assessed by a child psychologist. Children between 16 and 30 months 
old were tested with the Bayley Scales of Infant Development (BSID III)22 and older 
children were tested with the Wechsler Preschool and Primary Scale of Intelligence 
or the Wechsler Intelligence Scale for Children (WPPSI/WISC)23. The BSID reports 
a Developmental Score, the WPPSI/WISC consists of a verbal intelligence quotient 
(VIQ), performance intelligence quotient (PIQ) and total intelligence quotient 
(TIQ). All tests have a mean score of 100 and a standard deviation of 15.
Behavioral assessment
Behavioral development of the children was tested by having the mothers complete 
the Child Behavior Checklist (CBCL) for children from 1.5 to 5 or 6–18 years.24 
Outcome of this test consists of T- values on 6 different areas of the DSM-IV: affective 
problems, anxiety problems, attention deficit/hyperactivity problems, oppositional 
defiant problems, conduct problems, pervasive problems (1.5–5 year old) or somatic 
problems (6–18 year old). Results of these scores are divided into 3 categories, with 
T-values of 50–64.5 being normal, 64.5 to 69.5 subclinical and 69.5–100 clinical. 




Data are presented as mean ± standard deviation (SD) or as median (range).
Results
None of the 30 lithium-exposed children were born with congenital anomalies known 
to be associated with maternal lithium use. Mean ± SD birth weight was 3384 ± 
510 gram, mean gestational age was 38.0 ± 1.2 weeks and none of the children was 
asphyxiated (5min Apgar score <7) or needed respiratory support at birth. Seventeen 
out of 30 children were born by normal vaginal delivery. Ten children (of whom five 
were seen for follow-up) showed signs of neonatal toxicity: 4 had respiratory symptoms, 
4 nausea and vomiting (retching, refusal of nutrition), 2 hypoglycemia, 1 hypotonia 
and 1 hyperbilirubinemia. Two children had serum lithium values >0.8 mmol/L, of 
whom one had signs of neonatal toxicity. In addition to lithium, 9 out of 30 children 
were exposed to other psychotropic medications (4 were exposed to antidepressants, 4 
to benzodiazepines and 1 to an antipsychotic drug). One child had a ventricular septal 
defect with coarctation of the aorta and underwent successful surgical repair. Serum 
electrolytes, renal function and thyroid hormones were normal in all.
	  
 	  30	  children	  
of 	    	  22	  mothers	  
 	  22	  children	  
of 	  15	   	  mothers 	  
reached	  
8	   	  children	  
of 	  6	   	  mothers	  
not reached	  
17	   	  children	  
of 	  12	   	  mothers	  
agreed	  
5	   	  children	  
of 	  3	   	  mothers	  
refused	  
 	  15	  children	  
of 	  10	   	  mothers	  
available	  
for participation	  
2	   	  children	  
of 	  2	   	  mothers	  
not available	  
on testdates	  
Figure 1. Flowchart of included infants.




Six mothers (8 children) could not be reached for follow-up because they had moved 
without leaving a forwarding address or moved out of the country, 3 mothers (5 
children) refused participation and 2 mothers (2 children) were not available on test 
dates. Ten mothers were left, with a total of 15 children, to participate in the study. 
In figure 1 a flowchart can be seen of participating children and mothers.
Table 1 shows the baseline characteristics of the 15 children who participated in 
the follow-up study. No significant differences were found in baseline characteristics 
comparing participating and non-participating children in the follow-up study.
Results of the neurological and physical examinations are presented in table 2. One 
child had a minor neurological dysfunction (MND), but this result was without 
further clinical implications. In all other cases no neurologic abnormalities were 
found. Growth measurements were all within the normal range.
Table 2 also reports the results of the psychological examinations. Testing of cognition 
with WISC-III-NL, WPPSI-R and Bayley tests did not demonstrate any abnormality. 
One child had a low VIQ and TIQ, but the PIQ was normal. All other data were 
within the normal range. Most children had a lower score on the performance tests, 
especially on the subtest Block patterns, but this was not a significant deprivation. 
The child tested with the WPPSI-R had above average scores, so did one child tested 
with the Bayley test.
The results of the CBCL-questionnaire showed no abnormalities in the areas of 
Affective Problems, ADH, Conduct Problems and Pervasive Disorders and all scores 
were within the normal range. In the area of Anxiety Problems two children scored in 
the subclinical range, one of whom also scored in the subclinical range in the area of 
Somatic Problems. One child was in the subclinical range in the area of Oppositional 
Problems.
Developmental milestones were normal in all children. Parents mentioned hyperactivity 
and concentration problems in 3 children. Medical histories frequently reported viral 
upper airway infections, eczema in 4 children and allergies in 2. Two children received 
physical therapy when they were 1.5 to 4 years old to improve their gross motor skills. 
One child had transient motor problems at the age of 7.
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This study reports the long-term outcome of 15 children who were exposed to lithium 
in utero and were not breastfed. Neurological screening and growth measurements 
did not show significant abnormalities in the children, all were well within the normal 
range. Intelligence tests detected lower scores in the performance tests, especially in 
the Block pattern subtest, in nearly all children, but the difference with a control 
general population was not significant. Motor and behavioral development showed 
no significant abnormalities, based on the CBCL and developmental questionnaire.
The only study on follow-up of lithium exposed children was done by Schou in 
1976.16 In this follow-up study a questionnaire was sent to the psychiatrist or the 
general practitioner of the mothers of 60 children who had been exposed to lithium 
in utero. These doctors were requested to ask the mothers if any problems in physical 
or mental development had occurred in the lithium-exposed children and their non-
lithium-exposed siblings who served as a control group. No significant differences 
were found between both groups. However, this study was based on the subjective 
report of the mothers, never a study was done where a pediatrician and a psychologist 
examined the children. Our study comprised growth measurements and formal testing 
of neurological, cognitive and behavioral outcome in 15 children 3–15 years of age 
and shows that outcome of these children is indeed within normal limits.
Limitations of this study are the relatively small sample size, lack of a suitable control 
group, and use of other psychotropic medications. Because of the observational character 
of the study, no specific hypothesis was formulated in advance. Small differences 
may be difficult to detect due to the small group of children tested and the intrinsic 
limitations of the standard screening instruments for behavioral development.25 A 
possible negative finding may be the lower scores on the performance IQ (PIQ) tests, 
but further and more specific research needs to be done on this subject. As the lower 
scores of PIQ were not statistically significant, it was not necessary to investigate 
the role of potential confounding factors on cognitive development (maternal IQ, 
socioeconomic status, use of alcohol and tobacco). No suitable control group could 
be found, because it is almost impossible to identify children who were raised in the 
same situation and family, but without in utero exposure to lithium. This type of 
controls was not available to us. However, normal values of tests for psychological 
and behavioral development are based on a large cohort of children from the general 
population, which functions like a control group.
Based on our results we conclude that the children are developing normally after 




being exposed to lithium in utero and that no major developmental problems have 
evolved. This supports the thesis that continuing lithium therapy during pregnancy 
does not adversely affect the development of a child, and that it is rather safe to do so. 
This information may provide the counseling doctor and the bipolar woman more 
confidence in planning a safe pregnancy and continuing lithium treatment.
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Weekly maternal intravenous immunoglobulin (IVIG) is the cornerstone in antenatal 
treatment of fetal and neonatal allo-immune thrombocytopenia (FNAIT). The aim of 
this study was to describe the neonatal outcome and management in neonates with 
FNAIT treated antenatally with IVIG. 
Materials and methods
All neonates treated antenatally and delivered at our center between 2006 and 2012 
were included in the study. We assessed the neonatal outcome and management, 
including the occurrence of intracranial hemorrhage (ICH), platelet count at birth 
and need for postnatal platelet transfusions or postnatal IVIG treatment.
Results
A total of 23 neonates were included of which 12 (52%) had severe thrombocytopenia 
at birth (platelet count <50 x 109/L). Most neonates (75%, 9/12) with severe 
thrombocytopenia received a platelet transfusion after birth. None of the neonates 
required postnatal treatment with IVIG. Three neonates had petechiae and hematomas, 
without clinical consequences. One neonate suffered from ICH, which was detected 
just before the planned start of antenatal IVIG at 28 weeks’ gestation. 
Discussion
Our results suggest that antenatal maternal IVIG and, if necessary, postnatal matched 
platelet transfusions, are effective and safe for treatment of FNAIT.





Fetal and neonatal allo-immune thrombocytopenia (FNAIT) is the most common 
cause of isolated severe thrombocytopenia in the fetus and neonate.1-3 It is caused by 
maternal allo-antibodies against antigens of paternal origin on fetal platelets, resulting 
in platelet destruction and severe fetal and neonatal thrombocytopenia.4 In 80-95% 
of the affected cases, FNAIT is caused by fetomaternal incompatibility for human 
platelet antigen 1a (HPA 1a).5-8 Approximately 2% of the Caucasian women are HPA-
1a-negative (HPA-1bb), of which only 8-12% will become immunized and produce 
allo-antibodies.9-14 The most feared complication of severe neonatal thrombocytopenia 
is intracranial hemorrhage (ICH), with an incidence of 14-20% in untreated first 
pregnancies affected with FNAIT.5,15-17 The majority of ICH occurs at the end of the 
second trimester and clinical outcome are devastating for most cases.18,19
The main treatment goal in FNAIT is prevention of (intrauterine) ICH. The 
optimal antenatal management is controversial and includes an invasive strategy 
with repeated fetal blood sampling and intrauterine platelet transfusions 
(IUPT) or a non-invasive strategy with weekly maternal antenatal IVIG.6,20 
Our center, the Leiden University Medical Center (LUMC), is the national referral 
center for FNAIT-cases in the Netherlands. Our management changed over time from 
an invasive to a non-invasive strategy.6 Although antenatal IVIG administration has 
become the cornerstone of current treatment, questions remain about the optimal 
dose, best gestational age to start and the exact mechanisms of action.21 In addition, 
little is known about the optimal postnatal management. Treatment of first choice 
after birth is transfusion of matched platelets, but in case of emergency without 
immediate availability, random platelets are also given. Postnatal IVIG is effective 
in increasing platelet counts, but the response is much slower compared to platelet 
transfusions and the risk of destruction of transfused random platelets exists.15,16,22-24
The aim of this study was to evaluate the neonatal outcome and management in all 
FNAIT-cases treated antenatally with IVIG during a 6-year period.
Materials and methods
Study population
All infants with FNAIT, treated with antenatal maternal IVIG (Nanogam®) at our 
center between January 2006 and January 2012, were included in this study. All 
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these cases were already known due to a previously affected pregnancy and were treated 
according to a completely non-invasive protocol.6 Pregnancies were divided in standard 
and high risk groups, based on the presence or absence of a previous sibling with ICH. 
In the standard risk group (no sibling with ICH), antenatal IVIG was started at a 
gestational age of 28 weeks. In the high risk group (previous sibling with ICH), IVIG 
treatment was started earlier, at 16-18 weeks’ gestation. Between 2005 and 2008 the 
LUMC participated in the NOICH-trial, in which mothers were randomized for a 
dosage of 0.5 or 1 g/kg maternal weight. The trial was prematurely stopped in 2008 due 
to shortage of inclusions, however all FNAIT cases are still prospectively collected in an 
international web-based registry (www.medscinet.com/noich/).
Since 2008, dosage of IVIG in patients with standard risk pregnancies varies between 
0.5 g/kg and 1 g/kg maternal weight. Dosage of IVIG in high risk pregnancies is 1 
g/kg maternal weight. 
At birth, platelets were determined from the umbilical cord using a standardized 
flow cytometric method, in case of thrombocytopenia <100 x 109/L, platelet count 
determination was repeated manually. Neonates were examined to rule out the presence 
of hematomas and petechiae. A cranial ultrasound examination was performed in all 
neonates within 24 hours postpartum. Matched platelet transfusions were administered 
if platelet count was < 50 x 109/L in bleeding neonates or < 30 x 109/L in non-bleeding 
neonates. In 2010, the transfusion trigger for non-bleeding neonates was lowered to 20 
x 109/L. HPA-1bb/5aa-typed platelet concentrates were available 24 hours a day. In case 
of emergency (i.e. clinical bleeding) and no immediate availability of matched platelets, 
random platelets were transfused. When multiple matched platelet transfusions did not 
result in sufficient rise of platelet count, treatment with IVIG was considered. No strict 
criterion for the start of IVIG was maintained. Platelet counts were determined at least 
daily during the first days of life, until a spontaneous rise or stable level was observed. 
The postnatal protocol was independent of inclusion in the NOICH-study.
Data collection
Data were collected retrospectively and entered in a database, which included 
also data about previous pregnancies. Antenatal and postnatal baseline 
characteristics were collected and included HPA incompatibility type, dosage 
of IVIG, gestational age at start of IVIG, ICH in previous pregnancy, mode of 
delivery, gestational age at birth, birth weight and Apgar score <7 at 5 minutes. 
Outcome measures were platelet count at birth, presence of hematomas and/or 
petechiae, occurrence of ICH, number of needed postnatal platelet transfusions 




(matched or random), postnatal use of IVIG, course of platelet counts over time and 
neonatal outcome. 
Results
During the 6-year study period, 23 neonates with FNAIT treated with antenatal 
IVIG were included. Two pregnancies (9%) were considered high risk due to a sibling 
with ICH, IVIG dosage was set at 1 g/kg starting at 16 weeks’ gestation. Twenty-one 
(91%) pregnancies were considered as standard risk, of which 20 were treated from 28 
weeks’ gestation onward with 0.5 g/kg or 1 g/kg. Eight pregnancies were included in 
the NOICH trial and were randomized to receive either 1 g/kg (n=2) or 0.5 g/kg (n=6). 
One standard risk pregnancy was treated with 1 g/kg maternal weight antenatal IVIG 
at 35 weeks’ gestation, because of a delayed retrospective diagnosis of FNAIT in the 
previous pregnancy. Another pregnancy in the standard risk population started with 1 g/
kg IVIG at 28 weeks’ gestation, because of a detected antenatal ICH. No adverse effects 
of maternal IVIG therapy were reported. A flowchart of all included patients can be 
seen in figure 1. Baseline characteristics of the included patients are depicted in table 1.
Table 1. Baseline characteristics of included patients (n=23).
N = 23
HPA type 1a, n (%) 19 (83)
5b, n (%) 2 (9)
15a, n (%) 1 (4)
1a and 5b, n (%) 1 (4)
ICH in previous pregnancy, n (%) 2 (9)
Gestational age at start of IVIG 16 weeks, n (%) 2 (9)
28 weeks, n (%) 20 (87)
35 weeks, n (%) 1 (4)
Dosage IVIG 0.5 g/kg, n (%) 17 (74)
1 g/kg, n (%) 6 (26)
Caesarean delivery, n (%) 8 (35)
Neonates of mothers with miscarriages/spontaneous abortions, n (%)b 3 (13)
Gravidity 2.5 ± 1.1 (2-6)
Gestational age at birth, weeks a 37.3 ± 1.6 (33-39)
Birth weight, gram a 2922 ± 526 (1855-3730)
Apgar score <7 at 5 minutes, n (%) 0 (0)
a Value given as mean ± SD (range)
b Two included neonates were siblings, so in total two mothers in the population had miscarriages or spontaneous 
abortions.
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Figure 1. Flowchart of included patients.
Abbreviation:
GA: Gestational age.
Mean platelet count at birth was 91 ± 88 x 109/L (range: 6-277 x 109/L) and severe 
thrombocytopenia (platelet count < 50 x 109/L) was detected in 12 (52%) neonates. 
Mean platelet count at birth was 104 ± 89 x 109/L in neonates which received 0.5 
g/kg IVIG antenatally and 55 ± 83 x 109/L in those who received 1 g/kg IVIG.
In the group with severe thrombocytopenia, eight neonates required 1 matched 
platelet transfusion and one neonate needed 2 platelet transfusions, whereas in three 
neonates the platelet count increased spontaneously. None of the neonates received 
postnatal IVIG. Mean age at the time platelet count achieved a safe level above 150 
x 109/L was 3.0 ± 1.6 (1-7) days. Five infants were discharged with a stable platelet 
count between 100 and 150 x 109/L. Individual course of platelet counts of treated 
neonates is graphically shown in fi gure 2.
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Figure 2. Individual course of platelet count per day.
Legend: Dots indicate the time of platelet transfusions.
Routine cranial ultrasound was performed in all neonates. One neonate had an ICH, 
which was detected by coincidence during a routine fetal ultrasound at 27 weeks’ 
gestation, just 1 day before the planned start of IVIG treatment. Platelet count at birth 
was 6 x 109/L and the neonate had several petechiae and hematomas. One matched 
platelet transfusion was administered at birth with good increment. On the second 
day of life a MRI of the brain showed a left occipital porencephalic cyst, remnant 
of the antenatal ICH (figure 3). At 2 years of age, a physical and neurodevelopment 
assessment (using the Bayley Scales of Infant Development III)25 was performed 
showing a normal growth and neurodevelopment outcome. Petechiae were detected 
in two other neonates with platelets of 29 x 109/L and 26 x 109/L at birth, both had 
a good response with 1 matched platelet transfusion. 
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Figure 3. Neonatal cerebral MRI showing a large porencephalic cyst in the left occipital lobe. The cyst is a 
remnant of a large antenatal ICH, detected at 27 weeks’ of gestation.
Five neonates with severe thrombocytopenia were born after 2010, when platelet 
transfusion trigger in non-bleeding neonates was lowered from 30 x 109/L to 20 x 
109/L platelets. One of them (with a platelet count of 22 x 109/L without clinical 
bleeding) had a spontaneous rise and did not receive a platelet transfusion according 
to the new protocol. The other 4 infants had platelets <20 x 109/L (2) or petechiae or 
hematomas (n=2) as indication for a platelet transfusion. Table 2 provides an overview 
of the neonatal outcome.




Table 2. Neonatal outcome.
N = 23
Platelet count at birth, x 109/La 91.1 ± 88.1 (6-277)
Platelet count < 150 x 109/L, n (%) 16 (70)
Platelet count < 50 x 109/L, n (%) 12 (52)
Platelet count < 30 x 109/L, n (%) 9 (39)
Lowest platelet count, days a 1.5 ± 0.9 (1-4)
Petechiae and/or hematomas, n (%) 3 (13)
ICH, n (%) 1 (4)
Neonates receiving postnatal platelet transfusions, n (%) 9 (39)
Postnatal age when receiving platelet transfusions, days a 1.2 ± 0.7 (1-3)
Postnatal age PC > 150x109/L, days a 3.0 ± 1.6 (1-7)
a Value given as mean ± SD (range)
Discussion
This cohort study shows a favorable neonatal outcome in FNAIT after non-invasive 
antenatal maternal treatment with IVIG. Approximately one third (8/23) of the 
neonates required matched platelet transfusions at birth with a rise in platelets within 
a few hours and postnatal IVIG was not necessary. An antenatal ICH was detected 
in only 1 infant at 27 weeks of gestation, just before the start of antenatal IVIG. 
Despite the cerebral injury, the infant showed a normal neurobehavioral outcome at 
2 years of age. Non-invasive management of FNAIT with antenatal maternal IVIG 
and postnatal matched platelet transfusions seems to be effective and safe.
In this study, approximately one half (12/23) of the neonates had a platelet count at 
birth < 50 x 109/L. The incidence of severe thrombocytopenia found in this study is 
similar to the incidence reported in several other cohorts (range 34% to 61%).16,26,27 
Berkowitz et al reported a lower incidence of severe thrombocytopenia (14%), but 
they included only infants without siblings with severe thrombocytopenia or ICH.28 
A sibling with ICH or severe thrombocytopenia is one of the most important risk 
factors for recurrence of severe thrombocytopenia.29 Besides neonates with HPA1a-
incompatability, we also included cases with HPA5b-incompatibility (2) and HPA15a-
incompatibility (1). The incidence of severe thrombocytopenia reported in this study 
may be influenced by the fact that HPA5b incompatibility is associated with less severe 
thrombocytopenia.18,30
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The incidence of ICH in our study was 4% (1/23) and concurrent with the incidence 
reported by others (range 0-10%).5-7,16,26-28,31 The only infant with ICH in our study 
did not have a sibling with ICH and was therefore planned to start with IVIG at 28 
weeks of gestation (standard risk group). However an ICH was detected just 1 day 
before starting IVIG. Whether starting IVIG before 28 weeks of gestation could 
have prevented of the development of ICH is not known. Consensus on the optimal 
timing of starting the treatment with IVIG is currently lacking. In our study, severe 
thrombocytopenia at birth was not associated with an increased rate of ICH. As 
previously suggested, our study confirms the possible protecting effect of IVIG for ICH 
even without an increase in fetal platelet counts.27,32,33 In addition, all infants had an 
adequate and quick response on postnatal matched platelet transfusions and postnatal 
IVIG was not necessary. This positive effect of antenatal IVIG in combination with 
postnatal matched platelet transfusions was also reported in earlier studies.16,22,24 In 
contrast to our observations in human beings, reduction of bleeding complications in 
mouse studies with IVIG was accompanied by an increase of platelet counts.34
Several questions on the optimal IVIG treatment remain unanswered, including the 
optimal dose (0.5 or 1 g/kg), schedule (weekly or more frequently) and gestational 
age to initiate antenatal IVIG. Our study was not designed nor powered to analyze 
these issues and was primarily focused on postnatal management. Currently, a large 
international web-based registry of all FNAIT cases (prospective continuation after 
the NOICH-trial) may shed more light on this subject in the near future. Data on 
timing of antenatal intracranial hemorrhages with suggestions for gestational age to 
initiate antenatal IVIG have already been published.19
Prevention of ICH in unknown first cases of FNAIT may also be achieved using 
antenatal screening on HPA1a negative genotypes in all pregnant women. Still more 
studies suggest the level of maternal antibody titer during pregnancy as a possible 
predicting factor for severe thrombocytopenia, although the diagnostic value is not 
clear as reliable cut off levels were not repeatedly demonstrated yet.9,13,16 Kjeldsen et 
al suggested a policy of antenatal screening for immunized HPA1a negative pregnant 
women and performing a cesarean section at a gestational age of 36-38 weeks. Their 
incidence of ICH was 2 out of 170 immunized HPA1a negative women, although 
with lacking control group with at term vaginal delivery no strict conclusions can be 
drawn from this study.35 More research is needed to identify women at greatest risk 
in order to investigate the advantages of offering antenatal treatment with maternal 
IVIG in a more targeted way.
The retrospective design of this study is a limiting factor; we tried to minimize possible 




bias by using strict definitions and cut off values. Another limitation is the relatively 
small sample size, due to the rarity of this disease. However, sufficient retrospective 
evidence is needed to design and perform ethical justified randomized controlled 
trials. In conclusion, our study results suggest that non-invasive antenatal treatment 
of FNAIT with weekly maternal IVIG and, if necessary, postnatal transfusion of 
matched platelets is safe and effective. We recommend the use of matched platelets 
to non-bleeding neonates with a platelet count of < 20 x 109/L and to bleeding 
neonates with a platelet count < 50 x 109/L. In general, postnatal IVIG administration 
can be omitted. More research is needed to optimize dose and schedule of antenatal 
IVIG treatment and to detect more predicting factors of severe fetal or neonatal 
thrombocytopenia. 
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Patent ductus arteriosus (PDA) is a frequent complication in preterm infants. 
Ibuprofen and indomethacin (both COX-inhibitors) are used for pharmacological 
closure of PDA. In most centers a failed second course of COX-inhibitors is followed 
by surgical closure.
Our aim was to estimate the closure rate of clinically significant PDA after second 
and third courses of ibuprofen and record possible side effects.
A study population, consisting of 164 preterm infants (<32 weeks’ gestational 
age) with PDA admitted at our tertiary care center between November 2005 and 
September 2011, was retrospectively analyzed. Primary outcome was the closure 
rate after repeated courses of ibuprofen. The closure rate was similar after the first 
(109/164), second (24/43) an d third (6/11) course of ibuprofen (X2 = 2.1, p = 0.350). 
Late start of the first course of ibuprofen was a predictive factor for increased need of 
a second course (X2 = 4.4, p = 0.036). No additional side effects of multiple courses 
of ibuprofen were detected.
Conclusion
Repeated courses of ibuprofen are an effective and safe alternative for surgical closure 
and should be considered after failure of the first course of ibuprofen.





Patent ductus arteriosus (PDA) is a frequent complication in preterm infants, with 
a reported incidence of 28% in preterm infants with a gestational age <32 weeks up 
to 60-70% in those with a gestational age of <29 weeks.1,2 PDA is associated with 
increased neonatal mortality, chronic lung disease and necrotizing enterocolitis. The 
optimal management of PDA is still not clear as the evidence for and against treatment 
remains controversial.1,3-7
Indomethacin and ibuprofen (both COX-inhibitors) are commonly used for 
pharmacological closure of PDA and appear to be equally effective.7-9 However, 
ibuprofen has shown fewer side effects than indomethacin.7,10 One course of COX-
inhibitors resulted in a closure rate of 68-88% for indomethacin and 45-91% for 
ibuprofen. A second course led to a lower closure rate of 44-47% for indomethacin 
and 40-45% for ibuprofen.10-13
In most centers, closure failure after a second course of COX-inhibitors is followed 
by surgical closure. However, surgical closure has been associated with an increased 
risk of chronic lung disease, retinopathy of prematurity and neurodevelopmental 
impairment, compared to indomethacin therapy.14,15 A comparison of morbidity and 
neurodevelopmental outcome after surgical closure and pharmacological closure with 
ibuprofen is not available.
Only few studies report on the efficacy and safety of three courses of COX-inhibitors. Two 
small studies showed a PDA closure rate varying from 16 (3/19) to 43% (10/23) after a 
third course of indomethacin.10,16 The effect of a third course of ibuprofen has only been 
studied in two small studies with a closure rate varying from 19% (7/37) to 66% (2/3), 
and was associated with more renal complications than first and second courses.10,13
The aim of this retrospective study was to estimate the effectiveness and safety of second 
and third courses of ibuprofen on PDA closure and its potential, as an alternative 
for invasive and possible harmful surgical closure of the PDA. In addition, possible 
predicting factors for unsuccessful closure were investigated. 
Methods
Study population
We included all preterm infants (gestational age at birth <32 weeks) admitted to 
the Neonatal Intensive Care Unit (NICU) of the Leiden University Medical Center 
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between November 2005 and September 2011 with a PDA treated with ibuprofen. 
We excluded infants with congenital heart disease and infants referred to our center 
for surgical closure of the PDA. The Medical Ethics Committee of the Leiden 
University Medical Center did not require approval of this study because it consisted 
of retrospective chart review, nor did the medical ethics committee require written 
consent by the parents for their infant’s information to be (anonymously) stored in 
the hospital database and used for research.
Diagnosis of PDA was reached and confirmed using echocardiography (Aloka α10, 
Biomedic Nederland B.V., Almere, The Netherlands). First echocardiography was 
made when PDA was suspected, due to clinical symptoms such as widened pulse 
pressures, cardiac murmur, bounding pulses and/or significant respiratory disease. A 
PDA was considered clinically significant and requiring treatment, when the ductus 
was moderate to large in size (>1.5 mm) with evidence of left to right ductal shunting 
and an increased left atrium to aortic ratio.
Each ibuprofen course was prescribed as 10 mg/kg for the first dose followed by 
two additional doses of 5 mg/kg on consecutive days. Doses were administered 
intravenously with a 24 hour interval between each dose. Control echocardiography 
was routinely performed on the first day after the third dose of ibuprofen. A closed 
or hemodynamic insignificant ductus was scored as closed. No infants received 
prophylactic treatment with ibuprofen.
Indications for immediate surgical closure after one or two courses of ibuprofen were 
congestive heart failure and respiratory instability due to the PDA.
Data collection
Data were collected prospectively throughout the study period and entered in a 
dedicated database. Data for demographic and perinatal characteristics, as well as 
postnatal clinical conditions included birth weight, gestational age at birth, gender, 
intrauterine growth restriction, multiple gestation, pre-eclampsia, chorioamnionitis 
(defined as smelly amniotic fluid, maternal fever or signs of infection at birth), 
neonatal sepsis (defined as presence of clinical signs of infection with a positive blood 
culture), respiratory distress syndrome (RDS)17, duration of mechanical ventilation, 
need for postnatal steroids, bronchopulmonary dysplasia (need for oxygen therapy 
at a gestational age > 36 weeks)18, hypotension requiring inotropics, necrotizing 
enterocolitis (NEC)19, cystic periventricular leukomalacia20 and intraventricular 
hemorrhage21,22, duration of admission (until transfer to another secondary center) 
and neonatal mortality.




Primary outcome data were closure of the PDA after the first and (if necessary), second 
or third course of ibuprofen or after surgical ligation. We studied potential risk factors 
for failure of closure, including general characteristics (gestational age, birth weight), 
postnatal characteristics possibly pathophysiologic associated with PDA (RDS, 
duration of mechanical ventilation, NEC, neonatal sepsis) and age at start of ibuprofen 
for each individual course. Bronchopulmonary dysplasia, duration of admission and 
mortality were studied as possible consequences of failure of closure. We scored the 
following potential adverse effects of ibuprofen: oliguria (urine production <1.0 ml/
kg/hour) with or without renal failure (serum creatinine level >133 µmol/L23), severe 
thrombocytopenia (platelet count < 50 x 109/L after ibuprofen with platelet count > 
150 x 109/L before).
Statistical analysis
Data are reported as median values and ranges. Statistical analyses were performed 
with SPSS Version 18.0 (SPSS Inc., Chicago, IL). Data were not normally distributed 
and therefore analyzed using a Fisher’s Exact test. A p-value of <0.05 was considered 
significant. Study size was determined by the total number of exposed infants in the 
defined period.
Potential confounders in this study were all demographic and postnatal characteristics, 
mentioned previously. Confounding was minimized by using regression analysis. 
Infants with missing characteristics were excluded from regression analyses. 
Results
Between November 2005 and September 2011 931 preterm infants with a gestational 
age <32 weeks were admitted to our NICU. The incidence of PDA was 18% 
(170/931). Six infants were excluded from analysis because of referral to our center 
for primary surgical closure of PDA (n=6). A flowchart of the study population can 
be seen in figure 1. An overview of characteristics of the study population of preterm 
infants with PDA is shown in table 1.




Figure 1. Flowchart of included infants.




Table 1. Characteristics of the studied population.
N = 164
Gestational age at birth (weeks) a 27.0 (23-31)
Birth weight (grams) a 995 (525-2041)
Gender (male) – n (%) 81 (49)
Multiple gestation – n (%) 60 (37)
Chorioamnionitis – n (%) 6 (4)
Pre-eclampsia – n (%) 36 (22)
IUGR – n (%) 16 (10)
Respiratory distress syndrome – n (%) 125 (76)
Duration of mechanical ventilation (days) a 8 (0-36)
Postnatal steroids – n (%) 42 (26)
Bronchopulmonary dysplasia – n (%) 13 (8)
Hypotension – n (%) 64 (39)
Necrotizing enterocolitis – n (%) 12 (7)
Neonatal sepsis – n (%) 64 (39)
Periventricular leukomalacia (≥ grade 2) – n (%) 6 (4)
Intraventricular hemorrhage (≥ grade 3) – n (%) 15 (9)
Duration of admission (days) a 27 (3-138)
Mortality – n (%) 14 (9)
a Value given as median (range)
PDA closure rate was similar after the first (109/164), second (24/43) and third (6/11) 
course of ibuprofen (X2 = 2.1, p = 0.350) (table 2).
Table 2. Closure rate of ductus arteriosus after ibuprofen or ligation.
Courses of ibuprofen
1 2 3
Number of infants 164 43 11
Closed ductus after ibuprofen 109 24 6
Closed ductus after ligation 3 8 5
Unknown outcome 9
We studied several general characteristics, postnatal characteristics and age at start 
of ibuprofen for possible associations with failure of closure (as potential risk factors 
or consequences). Analysis of each ibuprofen course separately, showed a positive 
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correlation between postnatal age at start of the first dose of ibuprofen and the need 
for a second course of ibuprofen: the older the neonate (in terms of postnatal age at 
start of ibuprofen), the lower the chance of definitive PDA closure after one course 
of ibuprofen. The median age at the start of the first course of ibuprofen in the group 
with successful closure after one course was 4 days (range 2-24), compared to 5 days 
(range 2-19) in the group with unsuccessful closure after one course. Closure rate after 
the first course of ibuprofen significantly increased if ibuprofen treatment was started 
prior to postnatal day 5: 64/84 when started before day 5 versus 43/71 when started 
on day 5 or later (X2 = 4.4, p = 0.036).
Oliguria was observed in 10 infants (9 during the first, 1 during the second course 
of ibuprofen). One infant had an increased serum creatinine level >133 µmol/L 
during the first course of ibuprofen without oliguria. Four infants developed severe 
thrombocytopenia (platelet count < 50 x 109/L) during the first course of ibuprofen, 
without clinical signs of bleeding. All reported side effects were transient and resolved 
spontaneously. No relationship was found between adverse effects and the number of 
courses of ibuprofen. 
Discussion
This study shows that the closure rate of PDA after a second or third course of 
ibuprofen was similar to the closure rate after the first course and that multiple courses 
of ibuprofen were not associated with an increase in adverse effects.
Recently, two small studies reported on the PDA closure rate in a population of 
premature infants receiving multiple courses of ibuprofen. In a study in 182 preterm 
infants, Kushnir et al found closure rates for the first, second and third course of 92% 
, 54% and 19%, respectively10, whereas PDA closure rates in a study from Richards 
et al were 45%, 40% and 66%, respectively13. In comparison, the closure rates in our 
study cohort were 66%, 56% and 55%. The cumulative closure rate after all courses 
of ibuprofen was 71% (130/183) in the study by Kushnir et al10 and 69% (110/160) 
in the study by Richards et al13 versus 85% (139/164) in this study. Differences in 
closure rates between the studies are probably due to differences in study designs and 
methodology. The preterm infants in the study of Richards et al13 had a lower mean 
gestational age and birth weight (25.6 weeks, 757 gram) than the infants included in 
our study. In the study of Kushnir et al10 mean gestational age and birth weight were 
comparable (27.8 weeks, 1083 gram). 




Kushnir et al10 reported more adverse effects, i.e. an increase of serum creatinine levels 
and decrease of urine output in infants receiving more than one course of ibuprofen. 
We found no additional adverse effects during second and third courses of ibuprofen 
in our study, similar to the findings of Richards et al13. The most remarkable difference 
between the patient populations was the duration between the first and second course 
of ibuprofen (1 day in Kushnir et al, 6 days in Richards et al versus 3 days in our study 
population) and the second and third course of ibuprofen (1 day in Kushnir et al versus 
5 days in our study).10,13 The relatively short interval between the treatment courses in 
the Kushnir study might explain the increased risk of adverse effects.
The value of our study lies in the meticulous analysis of a large cohort, the focus on 
timely start of ibuprofen therapy and evaluation of current experience with repeated 
courses of COX-inhibitors versus surgical closure. The importance of this type of 
information is supported by the web-based questionnaire survey by Amin et al which 
evaluated the use of repeated courses of indomethacin in neonatal intensive care 
programs in the USA. Those centers using more than two courses of indomethacin, 
based their usage of a third course on local experience, because of lack of evidence 
on repeated courses in clinical literature.24 The reported harmful effects of surgical 
ductal closure, such as chronic lung disease, retinopathy and neurodevelopmental 
impairment, warrant in depth investigation of a pharmacological alternative without 
major side effects.14,15
Several factors have been associated with a higher closure rate after pharmacological 
treatment, including earlier age and a large ductal diameter (>2 mm) at start of the 
first course of ibuprofen.25 Our findings confirm the association between advanced 
postnatal age at the start of the first course and failure of ductal closure after the 
first course of ibuprofen. Closure rate after the first course of ibuprofen significantly 
increased if ibuprofen treatment was started prior to postnatal day 5. Similarly, in 
a study using indomethacin, re-opening of the ductus arteriosus with echographic 
luminal flow after the first course of indomethacin was more common in infants who 
received their indomethacin course at a higher postnatal age.26 None of these studies 
showed a relationship between closure rate and starting age of the second and third 
course of ibuprofen or indomethacin. 
The higher closure rate after the first course of ibuprofen, if started at a lower postnatal 
age, maybe due to the pharmacokinetic characteristics of ibuprofen. Ibuprofen is 
metabolized by the cytochrome P450 complex, especially the CYP2C9 and CYP2C8 
enzymes. Directly after birth these enzymes are absent in the serum, during the first 
week of life they increase to 33% of the adult serum level, independent of gestational 
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age. Therefore, the available concentration of ibuprofen decreases during the first week 
of life due to increased metabolism, resulting in less bio-availability for closure of the 
ductus.27,28 The reason why the starting age of the second and third course of ibuprofen 
does not influence the closure rate is not clear. Hypothetically, it could be expected 
that the fast increase in serum level of the CYP enzymes during the first week of life will 
flatten to a stable level in the next weeks, without influencing closure rate anymore.
The results of this study may have important consequences for clinical practice, 
especially when a second course of ibuprofen fails to close the PDA. Our data suggest 
that a third course of ibuprofen may be an effective alternative to surgical closure, 
without additional risks for pharmacological side effects. As shown in this study, 
closure rates of a second and third course of ibuprofen are independent of postnatal 
age at the start of the consecutive course. Therefore, advanced postnatal age may not 
be an argument in favor of surgical ligation instead of a second or third course of 
ibuprofen.
For many years PDA closure was the main goal in ductal management. More recently, 
various studies have raised important questions concerning the optimal management 
of PDA and the potential benefits of ductal closure.4,29,30 The management of PDA at 
our institution is to date still based on ductal closure. This will remain our standard 
of care unless new evidence is provided showing that ductal closure is associated with 
more disadvantages compared to conservative management.
Although our results add to the understanding of efficacy and safety of repeated courses 
of ibuprofen on PDA closure, we recognize there are several potential limitations. The 
retrospective design of this study is the first limiting factor. We tried to minimize 
possible bias by using strict definitions and cut-off values. A second limitation is the 
relatively small size of the study population receiving multiple ibuprofen courses. 
Nevertheless, retrospective and small studies are necessary to design future randomized 
controlled trials. Such a trial is urgently required to determine whether short and 
long-term outcome of pharmacological management of PDA with multiple courses 
of ibuprofen is better or worse than surgical closure. In addition, a larger prospective 
study using a third course of ibuprofen is needed to determine its pharmacological 
effects and side-effects.
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Coagulase negative staphylococci (CoNS) are the most common cause of neonatal 
sepsis in the Neonatal Intensive Care Unit (NICU). A minority of neonates does 
not respond to vancomycin therapy and develops persistent bacteremia, which may 
be treated with rifampin. We evaluated the use of rifampin in persistent CoNS 
bacteremia.
Methods
Retrospective study of 137 neonates with CoNS bacteremia during admission to a 
tertiary NICU between July 2006 and July 2009. Main outcome measures were total 
duration of bacteremia and the adequacy of vancomycin and rifampin therapy.
Results
137/1696 (8.0%) neonates developed a CoNS bacteremia. Eighteen were treated with 
rifampin because of persistent bacteremia (3 positive blood cultures at least 48 hours 
apart with clinical symptoms) or (a serious suspicion of ) an intravascular thrombus. 
Duration of bacteremia prior to rifampin therapy (8.0 ± 3.6 days) was positively 
correlated (p<0.001) to the total duration of bacteremia (10.3 ± 3.7 days). After 
starting rifampin therapy C-reactive protein (CRP) levels of all neonates declined 
and blood cultures became sterile after 2.3 ± 1.6 days. Vancomycin levels were not 
consistently measured in all neonates, resulting in late detection of subtherapeutic 
trough levels.
Conclusion
Rifampin may be effective in the treatment of persistent CoNS infections in neonates. 
Outcome may be improved by adequate monitoring of vancomycin trough levels.





Sepsis due to coagulase negative staphylococci (CoNS) is common in the neonatal 
intensive care unit (NICU). The incidence of CoNS sepsis varies between 1.3 and 
19.9%, depending on birth weight and gestational age.1-5 Most of these infections 
respond well to vancomycin, the first drug of choice. A minority of neonates develops 
a persistent staphylococcal bacteremia, which does not respond to vancomycin. 
For these neonates rifampin may be a safe and effective additive treatment to 
vancomycin.1,6-8 Interaction between vancomycin and rifampin in treatment of 
staphylococcal infections is ambiguous, as some studies demonstrate antagonism and 
others synergism or indifference.9-12 High concentrations of rifampin may result in 
antagonism.13,14 Rifampin is only effective as combination therapy, because resistance 
develops when rifampin is used as monotherapy.15
Through its highly lipophilic character, rifampin molecules can easily cross biological 
membranes, resulting in a wide tissue distribution.6,16 The efficacy of rifampin in persistent 
staphylococcal bacteremia is due to its abilities to enhance serum bactericidal activity 
and to penetrate phagocytic leukocytes for intraleukocytic killing of staphylococci.17
Pharmacokinetic research has demonstrated a positive correlation between the duration 
of rifampin therapy and its clearance, the equilibrium clearance is achieved after one to 
two weeks. The increase in clearance and decrease in half-life are probably due to auto-
induction of the metabolism of rifampin and require caution to maintain serum levels 
within the therapeutic range by adjusting the dose of rifampin, when necessary.6,16,18
Although CoNS bacteremia is common in NICUs and the treatment of persistent 
CoNS bacteremia with rifampin seems successful, previous studies were only small 
case reports or studies focusing on pharmacokinetics. The aim of this study was to 
evaluate the existing local guidelines for the use of rifampin therapy in persistent 




The study population of this retrospective chart review consisted of all neonates 
admitted to the neonatology department of the Leiden University Medical Center 
(LUMC) between July 2006 and July 2009. The Medical Ethics Committee of the 
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LUMC did not require approval of this study because it consisted of retrospective 
chart review, nor did the medical ethics committee require written consent by the 
parents for their infant’s information to be stored in the hospital database and used for 
research. Approval by the ethics committee and informed consent was not necessary 
as the patient data were analyzed anonymously.
Inclusion criterion was the presence of a positive blood culture for CoNS. Persistent 
CoNS bacteremia was defined as 3 positive blood cultures, spaced at least 48 hours 
apart, in combination with clinical symptoms of sepsis. The indication to start rifampin 
treatment was persistent CoNS bacteremia despite treatment with vancomycin and 
removal of indwelling catheters, or a non-persistent CoNS bacteremia in combination 
with a proven intravascular thrombus. Starting dose of rifampin was 10 mg/kg/day 
intravenously. 
Data collection
Data on demographic, perinatal and postnatal clinical characteristics were collected to 
provide an overview of baseline characteristics and included birth weight, gestational 
age, gender, exposure to prenatal and postnatal steroids, presence of chorioamnionitis, 
hyperglycemia, prolonged rupture of membranes (PROM), asphyxia, respiratory 
distress syndrome (RDS)19, bronchopulmonary dysplasia (BPD)20, necrotizing 
enterocolitis (NEC)21, cystic periventricular leukomalacia (PVL)22 and intraventricular 
hemorrhage (IVH)23,24. These data were collected from the neonatal charts and used to 
compare neonates with non-persistent and persistent CoNS bacteremia.
Primary outcome measures were the total duration of bacteremia and the adequacy of 
vancomycin treatment, estimated by following trough levels obtained after the initiation 
of vancomycin therapy until the tenth day of rifampin therapy. The desired range of 
trough levels of vancomycin was 5-10 mg/L, trough levels <5 mg/L were considered to 
be subtherapeutic and the desired range for peak levels was 20-30 mg/L. Other variables 
studied included plasma urea and creatinine levels and duration of vancomycin therapy.
Main outcomes for analysis of the group of rifampin treated neonates were total 
duration of bacteremia and rapidity of sterilization of blood cultures after the start 
of rifampin. Age at start of infection, CRP levels from the first day of CoNS positive 
blood culture until the tenth day of rifampin treatment, and duration and dose of 
rifampin treatment were additional variables among rifampin treated neonates.
Identification of CoNS isolates was performed by the microbiology department using 
Bactec Peds Plus bottles (Becton and Dickinson, Franklin Lakes, NJ USA). Blood 
cultures, complete blood count and CRP were drawn upon clinical suspicion of sepsis. 




CRP levels were determined daily during therapy with antibiotics. Vancomycin serum 
samples were drawn just before the third dose and 1 hour after administration of the 
third dose. When the dosage of vancomycin was changed, another serum sample 
was drawn around the second dose after the change. CRP levels were measured 
using a immunoturbidimetric assay (imCRP, detection limit ≥3 mg/L25) and serum 
vancomycin levels by a fluorescence polarization assay26.
CoNS bacteremia was an indication for removal of central venous lines and sonography 
for a remaining vascular thrombus.
Statistical analyses
Data are reported as mean values ± standard deviation, minimum and maximum, 
numerical values or categories. Analyses were performed with SPSS Version 16.0 (SPSS 
Inc., Chicago, IL). Numerical data were analyzed by bivariate Pearson correlation and 
unpaired T-tests, categorical data were analyzed using a chi-squared test. To correct for 
potential confounding effects, logistic regression analysis was done.
Results
In the period between July 2006 and July 2009 1696 neonates were admitted to the 
NICU with a mean birth weight of 1271 ± 663 gram and a gestational age of 29.2 
± 3.2 weeks. The incidence of CoNS bacteremia was 137/1696 (8%), 17 (12%) of these 
neonates developed a persistent CoNS bacteremia and in 3 of them an intra-vascular 
thrombus was identified. One neonate with a CoNS sepsis also had a S. aureus sepsis.
A flowchart of the included patients can be seen in figure 1.
Baseline characteristics of the included patients are listed in table 1. 
Newborn infants with persistent CoNS bacteremia had lower birth weights (p = 
0.008) and, independent of birth weight, more often hyperglycemia (p = 0.007), than 
infants with non-persistent CoNS bacteremia. Subtherapeutic vancomycin trough 
levels were equally divided among the groups with persistent and non-persistent 
CoNS bacteremia (p = 0.712).
Eighteen of the 137 neonates received rifampin treatment, started after 8.0 ± 3.6 days 
of CoNS bacteremia. 13/18 neonates had persistent CoNS bacteremia (in three of 
them an intravascular thrombus was found), 3/18 had an intravascular thrombus with 
a non-persistent CoNS bacteremia, 2/18 received rifampin because of increasing CRP 
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levels during vancomycin therapy in combination with severe thrombocytopenia and 
a serious suspicion of an intravascular thrombus.
Figure 2 shows the course of the CRP levels before and after the first CoNS positive 
blood culture, for both infants treated with and without rifampin (start of rifampin 

















































Figure 1. Flowchart of included infants
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Prenatal steroids – n (%) 0.668
0 doses 50 (43.1) 9(52.9)
1 dose 47 (40.5) 5 (29.4)
2 doses 19 (16.4) 3 (17.6)
Chorioamnionitis – n (%) b 9 (7.8) 1 (5.9) 0.784
PROM – n (%) c 14 (12.0) 2 (11.8) 0.981
Asphyxia – n (%) d 7 (5.8) 0 (0) 0.307
Gestational age (weeks) a 29.4 ± 3.3 28.0 ± 2.3 0.093
Birth weight (grams) a 1327 ± 686 874 ± 204 0.008
Gender (male) – n (%) 71 (59.2) 10 (58.8) 0.979
Multivariate p-value
(corrected for birth weight)
Hyperglycemia – n (%) e 8 (6.7) 8 (47.1) 0.007
IVH grade 3/4 – n (%) 9 (7.5) 0 (0.0) 0.999
Cystic PVL – n (%) 2 (1.7) 1 (5.9) 0.640
NEC grade 2/3 – n (%) 4 (3.3) 2 (11.8) 0.766
RDS grade 3/4 – n (%) 23 (19.2) 7 (41.2) 0.788
BDP – n (%) f 26 (21.7) 9 (52.9) 0.771
Postnatal steroids – n (%) 7 (5.8) 4 (23.5) 0.652
Died during admission – n (%) 3 (2.5) 1 (5.9) 0.754
a Value given as mean ± standard deviation
b Smelly amniotic fluid, maternal fever or signs of infection at birth
c Rupture of membranes >24 hours
d Presence of minimal 3 criteria:
1) Decelerative CTG or meconium containing amniotic fluid
2) Umbilical cord pH <7.10
3) Apgar score <5 after 5 minutes
4) Spontaneous respiratory depression >5 minutes after birth
5) Multiple organ failure
e Glucose levels of >10 mmol/L during >12 hours, treated with insulin >12 hours
f Need for oxygen-therapy at a gestational age of 36 weeks or at discharge






























Days before and after starting rifampin, started from the first day of CoNS positive blood 
culture 
Figure 4. Vancomycin trough levels (mg/L) of rifampin treated infants from the fi rst day of CoNS-positive 
blood culture until 10th day after starting rifampin treatment.
Table 2. Infection- and pharmacokinetic parameters of neonates treated with rifampin.
N = 18 Mean SD Min Max
Age at start of bacteremia (days) 5.4 2.7 1 11
Days of bacteremia before start of rifampin 8.0 3.6 2 14
Days of vancomycin/ceftazidim therapy before start of rifampin 8.9 4.5 2 20
Maximum peak level vancomycin (µg/ml) 26.7 3.5 20.0 32.0
Minimum peak level vancomycin (µg/ml) 20.3 4.7 12.8 28.0
Maximum trough level vancomycin (µg/ml) 10.8 2.6 7.3 15.9
Minimum trough level vancomycin (µg/ml) 7.3 3.6 3.5 15.9
CRP at start of rifampin (mg/l) 77.5 44.8 3 146
Maximum CRP during bacteremia (mg/l) 120.3 64.4 9 250
Duration of rifampin therapy (hour) 147.2 52.5 52 264
Dose of rifampin (mg/kg/day) 10.4 3.0 6.0 17.0
Rapidity of sterilization of blood culture after start of rifampin (days) 2.3 1.6 0 6
Total duration of bacteremia (days) 10.3 3.7 4 15
CRP levels from the fi rst day of a CoNS positive blood culture until the tenth day of 
rifampin therapy demonstrate a serious decline in CRP levels after starting rifampin 
therapy (fi gure 3). Indwelling catheters were removed before the fi rst CoNS positive 
blood culture (6 times), on the day of the fi rst CoNS positive blood culture (3 times) 
or after the fi rst CoNS blood culture (6 times, although in all these infants maximum 
CRP was achieved after removal of the catheter). Th e most important decline in CRP 
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occurred during the first 3 days after the start of rifampin. In these first 3 days the 
blood culture of most neonates became sterile, with a mean duration of 2.3 ± 1.6 days. 
Values of other infection and pharmacokinetic parameters of the neonates treated with 
rifampin are listed in table 2.
Before the start of rifampin all neonates received vancomycin as monotherapy (n = 1) 
or in combination with ceftazidim (until definitive identification and antimicrobial 
susceptibility testing of gram-positive cocci in clusters) (n = 17). The duration of 
vancomycin therapy was 8.9 ± 4.5 days. Ten neonates had adequate initial vancomycin 
levels, in 8 infants vancomycin dosage had to be readjusted. Vancomycin trough levels 
between the first day of CoNS positive blood culture and the tenth day of rifampin 
treatment are presented in figure 4. In contrast to vancomycin levels, rifampin levels 
were never obtained.
The presence of an intravascular thrombus did not correlate with the total duration 
of CoNS bacteremia or with the rapidity of sterilization of blood cultures after the 
start of rifampin treatment. 
Discussion
Comparing our incidence of CoNS bacteremia (8%) with other studies is difficult, 
as the composition of study populations vary. Most studies report a lower incidence, 
probably due to higher birth weights and gestational ages in these populations.2-4 One 
study reported an incidence of 19.9%, but neonates in this study had a lower gestational 
age.5 Effectiveness of rifampin treatment in persistent staphylococcal bacteremia in 
neonates has been demonstrated in several case reports and pharmacokinetic studies, 
in which speed of sterilization of the blood culture was the main outcome.1,6-8 Our 
data also show a substantial decline in CRP during the first days of rifampin treatment. 
To our knowledge, studies evaluating the treatment of CoNS bacteremia, focusing 
on the adequacy of monitoring and responding to vancomycin trough levels and the 
compliance with starting rifampin after 3 positive blood cultures with an interval of 
48 hours, have not been reported earlier.
This retrospective study has several limitations. The most important one is the small size 
of the study population (18 patients) available for evaluation of rifampin treatment. 
As most neonates with a CoNS bacteremia respond well to vancomycin, rifampin is 
given only incidentally. Another limitation is the absence of an appropriate control 
group. As 4 patients with a persistent CoNS bacteremia did not receive rifampin, 
this group was too small for comparison purposes. Comparison of the occurrence of 




vancomycin levels below the therapeutic margin between persistent and non persistent 
bacteremia appeared difficult, as vancomycin levels were not regularly assessed in all 
neonates, especially in neonates with a non-persistent bacteremia.
Comparing the groups with and without persistent CoNS bacteremia, significant 
differences were seen for birth weight and the presence of hyperglycemia. 
Hyperglycemia is caused by relative insulin deficiency and resistance, due to high 
levels of circulating cytokines and inflammatory markers during sepsis.27 Persistent 
bacteremia may increase the risk for developing co-morbidity such as hyperglycemia.
No clear statements can be made about the possible influence of adequate monitoring 
and the response to vancomycin trough levels on the risk of developing a persistent 
CoNS bacteremia. Because vancomycin levels were not consistently obtained in 
all neonates (especially in those without persistent CoNS-bacteremia), an accurate 
comparison of the occurrence of subtherapeutic vancomycin trough levels of infants 
with and without a persistent CoNS bacteremia was not possible.
Conclusion
Our results suggest that the treatment strategy for persistent staphylococcal bacteremia 
with rifampin may be effective, but can be optimized by improving the monitoring of 
vancomycin trough levels and minimizing the delay in starting rifampin treatment. 
If, in spite of adequate vancomycin levels, CoNS bacteremia becomes persistent, 
rifampin therapy may be started after 6 days of  bacteremia (3 positive blood cultures 
with a 48 hours interval after each).
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Pregnant women with Idiopathic Thrombocytopenic Purpura (ITP) can deliver neonates 
with severe thrombocytopenia. Clear evidence declaring the pathophysiological cause 
of this neonatal thrombocytopenia is lacking, as anti-platelet antibodies are not 
always detectable in maternal serum. Severe neonatal thrombocytopenia below 50 x 
109/L is reported in 8-13 % of the neonates from mothers with ITP and, intracranial 
hemorrhage (ICH) in 0-2.9%. Evidence about the optimal postnatal treatment is 
scarce. Our objective was to evaluate the outcome and management in neonates with 
passive ITP.
Materials and methods
All neonates from mothers with ITP born between 1980 and 2011 were included. 
Platelet counts during the first 10 days, presence of ICH and postnatal treatment 
were recorded. Maternal characteristics were analysed as possible risk factors for severe 
neonatal thrombocytopenia.
Results
Sixty-seven neonates were included. Severe thrombocytopenia (<50 x 109/L) occurred 
in 20/67 (29.9%) neonates. In 3 neonates platelet count rose spontaneously, 18 
neonates were treated (1 with persistent moderate thrombocytopenia) with: platelet 
transfusions (3), prednisone (2), IVIG (1), platelet transfusions and IVIG (11), 
platelet transfusions and prednisone (1). Recurrence of low platelet counts after 
transfusions were commonly seen. Risk factors for severe neonatal thrombocytopenia 
were a previous sibling with severe thrombocytopenia and low maternal platelet nadir 
during pregnancy.
Conclusion
In this cohort severe neonatal thrombocytopenia occurs more frequently than 
previously reported. To maintain a platelet count above 50 x 109/L often multiple 
transfusions and IVIG are required. Multiple transfusions may be avoided by starting 
IVIG, when platelet count falls below 50 x 109/L after the first platelet transfusion.





Idiopathic thrombocytopenic purpura (ITP) has an incidence of 1-10 in 10.000 
pregnant women; in one-third ITP presents during pregnancy.1,2 ITP is considered 
to be caused by auto-antibodies (IgG) against non-polymorphic platelet antigens, 
although antibodies cannot be detected in all women with ITP. Hypothetically these 
IgG antibodies can be transported through the placenta and can cause destruction 
of fetal platelets, but evidence for this hypothesis lacks.3,4 Severe thrombocytopenia 
(<50 x 109/L) in infants of mothers with ITP is however present in only 8-13% of the 
neonates. As opposed to fetal and neonatal allo-immune thrombocytopenia (FNAIT), 
severe bleeding complications such as intracranial hemorrhage (ICH) are more rare, 
with a reported incidence of 0-2.9%.1,2,5-12
Several risk indicators to predict severe neonatal thrombocytopenia have been 
explored. Most consistent are a previous sibling with thrombocytopenia2,6,9,10 and 
maternal splenectomy for therapy resistant ITP.1,6,11,13,14 Other factors such as maternal 
platelet counts (during pregnancy and delivery), presence of detectable anti-platelet 
antibodies in maternal serum and maternal treatment with corticosteroids and/
or intravenous immunoglobulin (IVIG) do not correlate with neonatal platelet 
count at birth.1,5,6,8,10,11,13,15 A small randomized controlled trial comparing maternal 
betamethasone with placebo showed no difference in neonatal platelet count.16
The natural course of platelet counts in neonates of mothers with ITP describes 
a platelet nadir at postnatal day 3-5, after which platelets will stabilize or rise 
spontaneously.1,3,12,17,18 However, the optimal postnatal treatment for severe neonatal 
thrombocytopenia is not evident and includes IVIG, platelet transfusions and/or 
prednisone. 2,4,6,7,15,19-21 Evidence on the neonatal outcome, risk factors and optimal 
management is scarce due to lack of studies. The aim of our study is to describe a 
relative large cohort of neonates, exposed to maternal ITP during pregnancy, with the 
focus on postnatal management and outcome.
Materials and methods
Study population
Neonates born between April 1980 and October 2011 from mothers with ITP, 
controlled during pregnancy by the hematology department of the Leiden University 
Medical Center were included in this study. Criteria for maternal diagnosis of ITP 
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were isolated thrombocytopenia for which other causes were excluded, normal or 
hypermegakaryocyte production in bone marrow, normal white and red blood 
cell counts. Mothers had been treated prior to pregnancy with corticosteroids, 
intravenous immunoglobuline (IVIG), platelet transfusions, cyclokapron, cyclosporin 
and/or splenectomy. Maternal autoantibodies were detected by direct platelet 
Immunofluorescence using anti-IgG and autologous platelets (if above 30 x 109/L). 
Serum antibodies were evaluated by ELISA distinguishing HLA class I antibodies 
and antibodies against platelet GP IIb/IIIa and Ib/IX. Detection of maternal anti-
platelet antibodies against autologous platelets or in serum was not systematically 
performed as this was not required for diagnosis of ITP, nor to distinguish gestational 
thrombocytopenia from ITP in mothers presenting with thrombocytopenia in 
pregnancy.22
At birth, platelets were determined from the umbilical cord or capillary as soon as 
possible on the first day of life; the neonates were examined physically for hematomas 
and petechiae. Since 1998 cranial ultrasound was routinely made in each neonate 
with a platelet count of < 50 x 109/L. Management protocols changed over time, so 
different postnatal treatment approaches were followed during the past decades. In 
most cases indication for platelet transfusion was a platelet count < 50x 109/L. Platelet 
counts were determined at least daily during the first 5 days of life or longer until a 
spontaneous rise or stable level was observed.
Postnatal neonatal treatment
Platelet transfusions were prepared from bloodgroup O-Rh-D negative donors by 
apheresis; platelets were leukocyte reduced by filtration prior to storage and volume 
was reduced prior to transfusion. The administered dose was approximately 20 x 109/
kg recipient body weight. For newborns with a gestational age below 32 weeks platelets 
were irradiated (25Gy).
Intravenous immunoglobulin (Immunoglobulin IV/Nanogam, Sanquin, Amsterdam, 
The Netherlands) was administered in standard dosage of 0.4 g/kg/day. Treatment was 
continued for 3-5 days, dependent on the severity of neonatal thrombocytopenia and 
response (i.e. a rising platelet count above 50 x 109/L during a couple of successive 
days).
Prednisone was started with a dosage of 2 mg/kg/day, which was decreased when 
platelet count increased.





Data were collected retrospectively and entered in a database. Antenatal and 
postnatal baseline characteristics were collected and included maternal diagnosis 
of ITP before or during pregnancy, maternal splenectomy before pregnancy, 
maternal medical treatment during pregnancy, nadir of maternal platelet count 
during pregnancy and last maternal platelet count before delivery, detectable 
maternal anti-platelet antibodies, mode of delivery, a previous neonate 
and platelet count of a previous sibling, gestational age and birth weight. 
Outcome measures were platelet count at birth, presence of hematomas and/or 
petechiae, occurrence of ICH, need for postnatal treatment, nature of postnatal 
treatment, duration of thrombocytopenia, interval to reach a platelet count > 50 x 
109/L and course of platelet counts over time. A subsequent fall or recurrence was 
defined as a platelet count of > 50 x 109/L directly after platelet transfusion, with a 
subsequent decline below 50 x 109/L within 24 hours after the platelet transfusion.
Statistical analysis
Data are reported as median (range), numerical values or categories. Statistical 
analyses were performed with SPSS Version 18.0 (SPSS Inc., Chicago, IL). As data 
were not normally distributed, data were analysed with non-parametric test such 
as Mann-Whitney test (numerical data) and Fisher’s Exact test (categorical data). 
Correlation was analysed using Spearman’s correlation. Confounding was prevented 
using regression analysis. Infants with missing baseline characteristics were excluded 
from regression analyses.
Results
A total of 83 neonates from 47 mothers with ITP were identified and deemed 
eligible for our study. Sixteen neonates from 13 mothers were excluded, because 
of missing data (including platelet counts at birth or platelet counts of the 
first neonatal days). Sixty-seven neonates of 41 mothers (including 3 twins) 
were included; for 18 mothers more than 1 pregnancy was analyzed. Seven 
mothers were excluded for one pregnancy, but included for another pregnancy. 
Splenectomy was performed before pregnancy in 16 mothers. Maternal anti-platelet 
antibodies were tested in 38/64 pregnancies and detected in 23 of them (60.5%). 
ITP was diagnosed prior to pregnancy in 53 pregnancies (82.8%). Antenatal 
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maternal treatment consisted of IVIG (n=3), prednisone (n=8), cyclokapron (n=2), 
a combination of prednisone and IVIG (n=4), a combination of IVIG and platelet 
transfusions (n=2), a combination of IVIG and cyclosporin (n=1) a combination 
of prednisone, IVIG and splenectomy in the second trimester (n=1). Median nadir 
of maternal platelet count during pregnancy was 75 x 109/L (range 5-347), the last 
maternal platelet count before delivery was 105 x 109/L (range 22-399). Baseline 
characteristics of the included pregnancies are depicted in table 1. None of the 5 
preterm born infants had severe thrombocytopenia. Only one of the neonates born 
from a mother with ITP diagnosed prior to pregnancy and pre-eclampsia had severe 
thrombocytopenia. In our study population the incidence of caesarean section was 
higher compared to the normal Dutch incidence (approximately 15%23). The reason 
for the high caesarean section incidence is not known. The indications for caesarean 
sections in our study population were not specifically scored; maternal ITP was not 
per se a contra-indication for vaginal delivery. 
Median neonatal platelet count at birth was 202 x 109/L (range 4-378). Thirty-four 
neonates had thrombocytopenia (< 150 x 109/L). Severe thrombocytopenia (platelet 
count < 50 x 109/L) was detected in 20 (29.9%) neonates in the first postnatal days, 
of which 8 (10.6%) had a platelet count of < 20 x 109/L. Only 5 neonates had severe 
thrombocytopenia at birth, whereas the majority developed severe thrombocytopenia 
within a few days postpartum. Two infants, which developed severe thrombocytopenia 
in the first 4 days of life, had a platelet count of >150 x 109/L at birth. Median age at 
the time of platelet nadir was 3.0 days (range 1-7) in all neonates. 
Routine cranial ultrasound showed no ICH in 14 neonates with severe 
thrombocytopenia. One neonate showed unilateral (left sided) polymicrogyria on 
cranial ultrasound and cerebral MRI (magnetic resonance imaging). In 6 neonates 
cranial ultrasound was not routinely performed, because they were born before 1998, 
since when the policy of routine cranial ultrasound for neonates with a platelet count 
below 50 x 109/L was introduced. These six neonates showed no clinical neurological 
signs of intracerebral bleeding. Petechiae were seen in 2 neonates: one had a platelet 
count of 84 x 109/L at birth and a nadir of 54 x 109/L on day 7; another had a platelet 
count of 42 x 109/L at birth and 5 x 109/L as nadir on day 6.




Table 1. Baseline characteristics of included pregnancies (n=64).
N = 64
Diagnosis of ITP before pregnancy, n (%) 53 (82.8)
Number of pregnancies a mother, n (%) 1 23 (56.1), 1 twin
2 14 (34.1), 2 twins
3 3 (7.3)
4 1 (2.4)
Maternal age (year)a 32.1 (22-40)
Maternal anti-platelet antibodies, n (%) Tested 38 (59.4)
Positive 23 (60.5)
Splenectomy before pregnancy, n (%) 16 (25.0)
Maternal treatment during pregnancy, n (%) No treatment 43 (67.1)
Prednisone 8 (12.5)
IVIG 2 (3.1)
Platelet transfusion 1 (1.6)
Cyclokapron 2 (3.1)
Prednisone and IVIG 4 (6.3)
IVIG and platelet transfusions 2 (3.1)
Prednisone, IVIG and splenectomy 1 (1.6)
IVIG and cyclosporin 1 (1.6)
Nadir of platelet count during pregnancy × 109/La 75 (5-347)
Last platelet count before delivery × 109/La 105 (22-399)
Maternal complications, n (%) ITP relatedb 3 (4.7)
Pregnancy complicationsc 7 (10.9)
Cesarean section, n (%) 19 (29.7)
Included infants (including 3 twins) N = 67
Gender (male), n (%) 32 (47.8)
Gestational age (weeks)a 39.0 (31-42)
Birth weight (gram)a 3240 (1345-4635)
a median (range)
b Bruising, petechiae, gingival bleeding
c Pre-eclampsia, HELLP or hypertension
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Table 2. Postnatal outcome and management in 67 neonates born after maternal ITP.
N = 67
Platelet count at birth x 109/La 202 (4-378)
Thrombocytopenia during first week of life, n (%) 101-150 x 109/L 34 (50.7)
51-100 x 109/L 25 (37.3)
21-50 x 109/L 20 (29.9)
< 20 x 109/L 8 (11.9)
Platelet nadir x 109/La 129 (4-315)
Age at platelet nadir (days)a 3 (1-7)
Petechiae, n (%) 2 (3.0)
Postnatal treatment (divided for infants with and without severe thrombocytopenia)
> 50 x 109/L (n=47) < 50 x 109/L (n=20)
No treatment 46 (68.6) 3 (4.5)
IVI 1 (1.5)
Platelet transfusion 1 (1.5) 2 (3.0)
Prednison 2 (3.0)
Platelet transfusion and IVIG 11 (16.4)
Platelet transfusion and prednisone 1 (1.5)
a median (range)
Postnatal treatment of infants with severe thrombocytopenia consisted of IVIG (n=1), 
prednisone (n=2), platelet transfusions (n=2), platelet transfusions combined with 
IVIG (n=11) and platelet transfusions combined with prednisone (n=1). IVIG was 
administered during median 5 days (range 3-5). Three children of one mother were 
treated with prednisone for a period of 11 days to 6 months, exact details of these 
neonates were not traceable (age of start was unknown in 1 case; exact duration of 
prednisone therapy given because of prolonged thrombocytopenia was unknown in 
all 3 cases), due to aged data sources. Three neonates had a quick spontaneous rise in 
platelet count and did not receive any treatment. Another neonate, without severe 
thrombocytopenia, but with a persisting platelet count between 50-60 x 109/L and 
petechiae, received 1 platelet transfusion. A general overview of neonatal outcome and 
management is given in table 2.
Fifteen neonates received median 3 platelet transfusions (range 1-6) per neonate, in 
12 neonates combined with IVIG (n=11) or prednisone (n=1). A subsequent fall 
to a platelet count of <50 x 109/L after the platelet transfusion occurred for 9/15 
(60.0%) after the first, 8/9 (88.9%) after the second and 6/8 (75.0%) after the third 




platelet transfusion. Seven out of 8 infants who had a fall of platelets below 50 x 109/L 
after the first platelet transfusion without IVIG, subsequently received IVIG, and 
platelets recovered after 2-6 platelet transfusions. IVIG was started at median 3 days 
(range 1-14) after the first determination of a platelet count < 50 x 109/L, median 
duration until IVIG treatment gained an increasing platelet count above 50 x 109/L 
was 1 day (range 0-8). Table 3 depicts a more detailed overview of the outcome of 
infants treated with IVIG and/or platelet transfusions.The course of platelet counts 
of severe thrombocytopenic neonates, receiving treatment for thrombocytopenia, is 
graphically shown in figure 1. 
Table 3. Characteristics of neonates treated with platelet transfusions and/or IVIG 
N = 16
Number of platelet transfusions a neonatea 3 (1-6)






Increment after first platelet transfusion x 109/L a 52 (3-147)
Decline of platelet count < 24 hours after platelet transfusion x 109/L a 66 (15-163)
Interval of start IVIG, after first platelet count < 50 x 109/L (days)a 3 (1-14)
Duration until platelets count > 50 x 109/L and increasing after start IVIG (days)a 1 (0-8)
a median (range)
b Fall of platelet count to < 50 x 109/L after platelet transfusion
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Figure 1. Course of neonatal platelets of all treated neonates per day (n=18).
Legend: Each line indicates one neonate. Black dots indicate the timing of platelet transfusions. Red squares 
and line indicate the start and stop of IVIG therapy. Blue triangles indicate start of prednisone therapy. 
Figure 1 shows that none of the infants receiving treatment for severe thrombocytopenia 
had a stable and/or rising platelet count above 50 x 109/L before the third day of life. 
Only one of the three neonates with spontaneous rise of platelet counts (without 
treatment), had this rise already on the second day of life (the other two neonates had 
their nadir below 50 x 109/L on day 6).
Median duration of thrombocytopenia (in all neonates with platelet counts < 
150 x 109/L) was 11 days (range 3-58). Th irteen of the thirty-four neonates with 
thrombocytopenia were not followed until a platelet count of >150 x 109/L was 
achieved, but had a stable or rising platelet count between 50-150 x 109/L (n=13). 
In neonates with severe thrombocytopenia platelet counts achieved a safe level above 
50 x 109/L within median 2.5 days (range 1-17). One neonate received an additional 
course of IVIG at the age of three weeks, because of a late relapse, with an adequate 
increment.




Two maternal risk factors for severe neonatal thrombocytopenia were identifi ed, 
including having an earlier neonate with severe thrombocytopenia (p = 0.032) and 
a low maternal platelet nadir during pregnancy (p = 0.031). Th ree mothers had 3 
infants and 2 mothers had 2 infants with severe neonatal thrombocytopenia. Platelets 
at birth and platelet nadir of the fi rst and second sibling were highly correlated (p = 
0.001 in Spearman’s correlation) in 18 mothers with more than 1 pregnancy (total of 
43 neonates), this correlation can be seen in fi gure 2. We didn’t found a relationship 
between detectable circulating maternal anti-platelet antibodies and severe neonatal 
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Platelet nadir of second sibling x 109/L 
Figure 2. Correlation between platelet counts at birth of the fi rst two siblings of mothers with ITP during 
pregnancy.







Nadir of maternal platelet count during pregnancy 0.002 0.015
Last maternal platelet count before delivery 0.038 0.084
Splenectomy 0.530
Diagnosis of ITP before current pregnancy 0.151
Mode of delivery 0.384
Detectable maternal anti-platelet antibodies 0.271
Severe neonatal thrombocytopenia in sibling 0.003 0.016




In this retrospective study the incidence of severe neonatal thrombocytopenia due 
to maternal ITP is high (29%) with a low incidence of bleeding complications. We 
report on 20 cases of severe thrombocytopenia, with only 2 cases of symptomatic 
thrombocytopenia with transient petechiae. A variety of postnatal treatment was 
used reflecting the lack of international consensus on optimal initial management. 
The effect of platelet transfusions was often short with frequent recurrence to a low 
platelet count, requiring additional transfusions and/or IVIG treatment. Our study 
is one of the larger reporting and analysing the effect of different postnatal treatment 
strategies. Especially analysing increments after platelet transfusions (currently only 
recommended for severe bleeding in several guidelines) and reporting individual 
courses of platelet counts was not performed earlier.21,24
Our incidence of severe neonatal thrombocytopenia seems high (29%), but we described 
all neonates with severe neonatal thrombocytopenia in the first postnatal days, in 
contrary to the majority of other studies reporting only severe thrombocytopenia at 
birth.2,5,7 The incidence of severe thrombocytopenia at birth was only 6% (4/66) in this 
study, which is comparable with reported incidences by others (8-13%).2,5-8 The high 
incidence could also be due to selection bias, because the more complicated cases were 
more likely to be referred to our tertiary care center (such as mothers with an earlier 
neonate with severe thrombocytopenia). As platelet counts of excluded neonates were 
not known, reporting bias caused by their exclusion can not be ruled out. One neonate 
in our study had severe cerebral injury of antenatal origin (unilateral polymicrogyria). 
Polymicrogyria is associated with prenatal events including congenital infections, 
chorioamnionitis, genetic syndromes, metabolic disorders and vascular events. 
Hypothetically, polymicrogyria in this infant may have resulted after an antenatal ICH 
due to thrombocytopenia. However, as other causes of polymicrogyria could not be 
ruled out and bleeding sequels could not be visualized, the occurrence of an antenatal 
ICH is uncertain. Follow-up at the age of 2 year showed hemiplegia on the right 
side.25 In agreement with other studies, we found severe neonatal thrombocytopenia 
in a sibling a risk factor for severe neonatal thrombocytopenia.6,9,10 We also observed 
an association with a low maternal platelet count during pregnancy.4,7 Evidence about 
associations between neonatal platelet counts and several maternal factors is conflicting, 
as most large studies show a lack of association with maternal platelets, antibodies and 
timing of diagnosis, whereas more severe neonatal thrombocytopenia in mothers which 
underwent splenectomy was quite frequently described.1,5,6,9,13




In the analysis of neonatal course of platelet counts, the effect of postnatal platelet 
transfusions was frequently short. Only 6/15 infants did not have a subsequent fall after 
their first platelet transfusion, although 3 of them were already treated with IVIG. Also 
after the second, third and fourth platelet transfusion recurrence of low platelet counts 
were common. With a median duration of 1 day (range 0-8) after starting IVIG until 
an increasing platelet count above 50 x 109/L was achieved, these results may indicate 
that IVIG should be started earlier than was done in this population (median 3 days 
after the first platelet count of < 50 x 109/L), to avoid multiple platelet transfusions. 
Otherwise, as 3 patients showed spontaneous improvement and 3 patients came to a 
persistent safe platelet level after one platelet transfusion, IVIG can be withheld in a 
substantial proportion of infants. Platelet transfusions can be considered in particular 
for neonates with a very low platelet count at birth, with the expectation that in the 
majority platelets will further decrease after birth, to tide over the period before IVIG 
will become effective. Only 3 patients received prednisone, not allowing conclusions 
to be drawn from our data.
We confirm the greatest risk of neonatal passive ITP to occur postpartum with the 
lowest platelet count at 3 days after birth. Lacking, apart from the neonatal platelet 
count of a previous sibling, risk indicators for delivering a severely thrombocytopenic 
neonate, focus should be turned to postnatal management.9,11 In this respect this 
retrospective report is of clinical importance as only two studies could be found that 
reported on neonates receiving postnatal platelet transfusions, IVIG or prednisone. 
One study described the effect of postnatal IVIG in 11 neonates, in some cases 
combined with steroids or platelet transfusions. No significant increments after 
platelet transfusions as single therapy were reported, but they did not analyze this 
in detail and individually. IVIG (eventually combined with steroids) had a success 
rate of 75%.26 Another study described a series of 6 neonates with disappointing 
increments after 5 days of IVIG, a subsequent 5 days of prednisone therapy resulted 
in platelet counts of >150 x 109/L in all 6 infants.27 This study suggested preferring 
prednisone above IVIG as postnatal therapy, but the adequate platelet increase after 
5 days of prednisone could also be a combined effect of IVIG and prednisone. We 
were the first study analyzing the individual platelet response of neonates with severe 
thrombocytopenia on platelet transfusions and IVIG.
This study has several limitations, of which the retrospective character is the first one. 
The sample size was relatively large, compared to other reported populations, however 
66 cases is still not a number on which very reliable statistical analyzes are applicable. 
In regression analysis for multiple variables with such a small sample size, a p-value of 
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< 0.01 would be more appropriate and preferable. Missing data was another limiting 
factor, which was caused by the need to collect cases from 30 years ago to have a sample 
size as large as possible and led to the exclusion of 16 neonates from 13 mothers. All 
three limitations can create considerable biases, but are the direct consequence of the 
rarity of the described condition, which makes it really difficult to collect enough 
cases to apply statistics. With strict cut-off values and definitions we tried to reduce 
the risk for possible bias as much as possible. Confirmation of our observations in a 
larger prospective cohorts in future studies is needed trough multicenter international 
collaboration reporting on all newborns. As it may take weeks before platelet counts 
are completely recovered, it would be very valuable to look for long term beneficial 
and adverse effects of different postnatal treatment strategies.
We can conclude that despite severe neonatal thrombocytopenia due to maternal ITP 
during pregnancy was fairly high in our series, severe bleeding manifestations were 
rare. As platelet nadir is seen within the first 7 days postpartum, bleeding risks are the 
highest in the first week, and daily platelet count control is necessary until a stable or 
rising safe platelet count above 50 x 109/L is observed (as advised in guidelines).20,24,28 
In addition should each individual case be evaluated precisely, to determine if daily 
platelet count measurement is really necessary or once in two days will suffice.
When a platelet transfusion fails to result in a stable increase of platelet counts, further 
platelet transfusions are not advised without IVIG treatment. Especially, because in 
a substantial number of neonates it takes some days until IVIG becomes effective, 
early start is preferable to achieve a safe platelet count of > 50 x 109/L more quickly. 
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Hyperglycemia in premature infants is associated with increased morbidity and 
mortality, but data on long-term outcome are limited. We investigated the effects 
of neonatal hyperglycemia (blood glucose ≥10 mmol/l, treated with insulin for ≥12 
hours) on growth and neurobehavioural outcome at 2 years of age.
Methods
Retrospective follow-up study at 2 years of age among 859 infants ≤32 weeks of 
gestation admitted to a tertiary neonatal center between January 2002 and December 
2006. Thirty-three survivors treated with insulin for hyperglycemia and 63 matched 
controls without hyperglycemia were evaluated at a corrected age of 2 years. 
Outcome measures consisted of growth (weight, length, and head circumference) 
and neurological and behavioural development.
Results
66/859 (8%) infants ≤32 weeks of gestation developed hyperglycemia. Mortality 
during admission was 27/66 (41%) in the hyperglycemia group versus 62/793 (8%) 
in those without hyperglycemia (p<0.001). Mortality was higher in infants with 
hyperglycemia with a birth weight ≤1000 gram (p = 0.005) and/or gestational age of 
24-28 weeks (p = 0.009) than in control infants without hyperglycemia. Sepsis was 
more prominent in infants with hyperglycemia and a birth weight of >1000 gram (p 
= 0.002) and/or gestational age of 29-32 weeks (p = 0.009) than in control infants 
without hyperglycemia. Growth at 2 years of age was similar, but neurological and 
behavioural development was more frequently abnormal among those with neonatal 
hyperglycemia (p = 0.036 and 0.021 respectively).
Conclusion
Mortality was higher in very preterm infants with hyperglycemia treated with insulin 
during the neonatal period. At 2 years of age survivors showed normal growth, but 
a higher incidence of neurological and behavioural problems. Better strategies to 
manage hyperglycemia may improve outcome of very preterm infants.





Hyperglycemia is a common problem in very preterm infants. Among extremely low 
birth weight infants the incidence of neonatal hyperglycemia is estimated to be between 
45% and 80%.1-3 This is possibly an under-estimation as 50% of the abnormalities in 
glucose levels are not detected by standard intermittent sampling and the incidence 
is also influenced by the use of different definitions.4,5 Accurate monitoring of blood 
glucose levels is clinically important, because abnormalities in glucose homeostasis 
can have serious short term consequences. Hyperglycemia is associated with increased 
mortality, which is significantly related to the duration of the hyperglycemia.6,7 A 
higher incidence of retinopathy of prematurity and intraventricular hemorrhage 
(IVH) grade 3 and 4 has also been reported.7,8
Prematurity is an important risk factor in the complex pathogenesis of hyperglycemia. 
Insulin resistance develops due to a high circulating level of inflammatory markers, 
cytokines and catecholamines. Consequently, glucose production in the liver is not 
inhibited. The pancreas needs to produce insulin to compensate, but is probably 
unable to do so due to immature beta-cells, leading to relative insulin deficiency.7,9,10
Since twenty-five years continuous insulin infusion is used, nevertheless in many 
centers restriction of glucose intake is still the first step in treatment of hyperglycemia.5
Comparison of these interventions has demonstrated the efficacy of continuous insulin 
infusion in glucose control. Infants treated with insulin had a higher glucose intake, 
a higher weight gain, less sepsis and an increased endogenous insulin production.11,12 
The benefit of early elective insulin therapy in the prevention and treatment of 
hyperglycemia has been demonstrated in critically ill adults, but is questionable in 
premature infants. Although early elective insulin therapy decreases hyperglycemia, 
it significantly increases the incidence of hypoglycemia and mortality by 28 days.13-15
Whereas the short term effects of neonatal hyperglycemia in very preterm infants 
have been reported, less is known about the effects of hyperglycemia on growth 
and neurobehavioural outcome. The aim of this retrospective follow-up study was 
to determine the possible effects of hyperglycemia on growth and neurobehavioral 
development by comparing very preterm infants with and without a history of 
neonatal hyperglycemia at the corrected age of two years.





The study population consisted of 859 very preterm infants (≤32 weeks) admitted to 
the Neonatal Intensive Care Unit (NICU) of the Leiden University Medical Center 
between January 2002 and December 2006. Neonatal data and data on growth and 
neurobehavioural outcome at the corrected age of 2 years were collected from the 
charts in the tertiary neonatal center and the regional hospitals where these infants 
were regularly seen for follow-up. The Medical Ethics Committee of the Leiden 
University Medical Center did not require approval of this study because it consisted 
of retrospective chart review, nor did the medical ethics committee require written 
consent by the parents for their infant’s information to be stored in the hospital 
database and used for research.
Hyperglycemia was defined as at least 2 blood glucose levels of ≥10.0 mmol/L (180 
mg/dL) during a 12-hour period. Insulin treatment was started at 0.05 U/kg/h14 when 
hyperglycemia persisted after these 12 hours, despite reduction of glucose intake to 
5-6 mg/kg/min. The insulin dosage was tapered after blood glucose levels dropped 
to <10 mmol/L. The cohort of exposed infants consisted of all preterm infants with 
neonatal hyperglycemia and the unexposed cohort was a matched selection of preterm 
infants admitted during the same timeframe, but without hyperglycemia (and without 
short-lived hyperglycemia <12 hours) and insulin therapy. The infants were matched 
by birth weight (± 0.1 kg), gestational age (± 1 week), gender, and date of admission 
(a period of ± 1 year was preferred). Each exposed infant was matched to 2 unexposed 
controls. The exclusion criteria for both exposed and unexposed infants were major 
congenital anomalies and chromosomal abnormalities. The study size was determined 
by the number of exposed infants during the study period and the availability of 
matches.
Data collection
Blood glucose levels were measured in whole blood using the glucose oxidase method 
(Siemens RapidPoint 400/405 system, Siemens Healthcare Diagnostics B.V., Breda, 
The Netherlands). Frequency of glucose level measurements was based on clinical 
and laboratory findings. During the first week after birth blood glucose levels were 
measured at least 6 times a day, thereafter glucose levels were measured at least 3 times 
a day. In the acute phase of hyperglycemia, glucose levels were measured regularly with 
intervals of approximately 1-2 hours.




Data for demographic and perinatal characteristics as well as postnatal clinical 
conditions of all infants were collected from the charts and included birth weight, 
gestational age, length of stay (as an indicator of severity of illness), gender, 
exposure to prenatal and postnatal steroids, presence of chorioamnionitis, sepsis, 
prolonged rupture of membranes (PROM), respiratory distress syndrome (RDS)16, 
bronchopulmonary dysplasia (BPD)17, necrotizing enterocolitis (NEC)18, cystic 
periventricular leukomalacia (PVL)19 and intraventricular hemorrhage (IVH)20,21.
For the exposed infants the mean, minimum and maximum glucose levels, glucose 
intake and insulin infusion rate were calculated for the first 5 days after the onset 
of the hyperglycemia episode or until the end of the hyperglycemia episode if 
the episode lasted longer than 5 days. Additionally, duration of hyperglycemia, 
frequency of hypoglycemic periods, duration of insulin infusion, mean serum sodium 
concentration, maximum daily percentage of inhaled oxygen and maximum infusion 
rate of inotropic drugs (dobutamine and dopamine), were recorded.
Outcome data collected at the corrected age of 2 years (± 3 months) included weight 
(kg), length (cm), head circumference (cm), and neurobehavioral development. 
Neurological outcome was classified into 3 groups: normal, mildly abnormal 
(detectable but not disabling abnormalities of tone and reflexes, presence of abnormal 
movements or asymmetry) and severely abnormal (disabling abnormalities) according 
to the neurological examination by Hempel.22 Behavioural outcome was scored normal 
or inadequate based on the Child Behavior Checklist/2-3 (CBCL/2-3)23 completed 
by the parents or orally by the clinic pediatrician.
Statistical analysis
Data are reported as mean values ± standard deviation, numerical values or categories. 
Statistical analyses were performed with SPSS Version 16.0 (SPSS Inc., Chicago, IL). 
Numerical growth parameters were analyzed with an unpaired T-test. The categorical 
data for behavioural and neurological outcome were analyzed using a chi-squared test.
Subgroup analyses were performed for subgroups in gestational age (24-28 and 29-32 
weeks) and birth weight (≤1000 gram and >1000 gram). Potential confounders in this 
study were gestational age, gender, birth weight, length of stay, exposure to prenatal 
and postnatal steroids, presence of severe RDS, sepsis, PROM, chorioamnionitis, 
NEC, BPD, PVL and IVH. Confounding was prevented by matching and using 
multivariable regression analysis for analyzing mortality and morbidity, as well as 
growth, neurological and behavioural development. Infants with missing baseline 
characteristics were excluded from regression analyses.




Between January 2002 and December 2006 a total of 859 very preterm infants 
with a gestational age less than 33 weeks were admitted for neonatal intensive care. 
Mean gestational age was 29.4 ± 2.0 weeks and birth weight 1323 ± 410 gram. Fifty-
six percent was male. Prenatal steroids were administered to 63% of the mothers. 
Chorioamnionitis and PROM were present in 13 and 27% respectively. Twenty-nine 
percent of the infants developed sepsis, 6% IVH grade 3 or 4, 3% cystic PVL, 2% NEC 









































Figure 1. Flowchart of included patients.
Postnatal steroids were administered to 10% of the infants. Hyperglycemia occurred 
in 66 (8%) infants of whom 53 had a birth weight of ≤1000 gram, the incidence in 
this subgroup was 25%. The mean age at onset of the hyperglycemia episode was 3.2 
± 3.7 days. Twenty-seven out of 66 infants with hyperglycemia (41%) died during 
admission versus 62/793 (8%) infants without hyperglycemia. Six of the remaining 
39 infants with hyperglycemia were excluded from this follow-up study because of 
major congenital anomalies (1) and loss to follow-up (5). Emigration (1), placement 
in an unknown foster home (1) and no appearance at follow-up appointments 
(3) were the reasons for the loss to follow-up. These infants were excluded from 




the analysis together with their unexposed matches. For 3 exposed infants only 1 
unexposed match was available. The complete follow-up population consisted of 96 
infants; a flowchart can be seen in figure 1.
Table 1. Baseline characteristics of included patients in the follow-up study.






Gestational age (week) a 28.2 ± 2.2 28.2 ± 2.2 1.000
Birth weight (gram) a 962 ± 316.4 1008 ± 292 0.478
Length of stay (day) 47.2 ± 32.5 25.7 ± 45.1 0.017
Gender (male) - n (%) 21 (64) 39 (62) 1.000
Prenatal steroids 0.721
0 doses 12 (36) 21 (35)
1 dose 13 (39) 21 (33)
  >1 doses 8 (24) 20 (32)
Chorioamnionitis - n (%) b 2 (6) 6 (10) 0.711
PROM - n (%) c 9 (27) 14 (22) 0.620
Postnatal clinical conditions
Sepsis - n (%) d 21 (64) 37 (59) 0.667
IVH grade 3/4 - n (%) 3 (9) 3 (5) 0.411
RDS grade 3/4 - n (%) 10 (33) 19 (30) 0.818
Cystic PVL - n (%) 0 (0) 2 (3) 0.544
NEC grade 2/3 - n (%) 1 (3) 0 (0) 0.334
BPD - n (%) e 20 (61) 25 (40) 0.056
Postnatal steroid exposure - n (%) 10 (30) 13 (21) 0.321
a Value given as mean ± standard deviation
b Chorioamnionitis was defined as smelly amniotic fluid, maternal fever or signs of infection at birth.
c PROM was defined as rupture of membranes >24 hours.
d Sepsis was defined as a positive blood culture.
e Need for oxygen-therapy at a gestational age of 36 weeks or at discharge
An overview of the baseline characteristics of included patients is given in table 1. The 
exposed group had a significantly longer length of stay than the unexposed group, 
reason why statistical correction for confounders by regression analysis was done.
Table 2 shows growth and development at 2 years of corrected age. Weight, length, head 
circumference were not different in the exposed cohort compared to the unexposed 
cohort. The incidence of an abnormal neurological and behavioural outcome was 
higher in the exposed group (p = 0.036 and 0.021 respectively).
26737 Lugt.indd   95 07-10-13   15:49
Chapter 7
96
Table 2. Growth and development at 2 years of corrected age.






Head circumference (cm) 47.8 ± 1.9 48.0 ± 1.8 0.613
Length (cm) 85.7 ± 4.0 85.0 ± 3.9 0.410
Weight (kg) 11.0 ± 1.5 11.0 ± 1.3 1.000
Neurological outcome - n (%) 0.036
Normal 16 (48) 47 (75)
Mild abnormal 12 (36) 12 (19)
Severe abnormal 5 (15) 4 (6)
Behavioural outcome - n (%) 0.021
Normal 17 (52) 48 (76)
Delayed 16 (48) 15 (24)
Analyses of the data on the hyperglycemia episodes (table 3) showed some significant 
relations. Mean and maximum glucose levels on the third and fourth day of the 
hyperglycemia episode correlated with mortality (mean: p = 0.046, maximum: p = 
0.041). Infants with a mean glucose level >8.0 mmol/L (144 mg/L) or a maximum 
glucose level >9.5 mmol/L (171 mg/L) on the third and fourth day had a higher 
mortality rate (p = 0.042 and p = 0.030, respectively). All hypoglycemia episodes 
were brief events which were corrected quickly. Neurobehavioural outcome, growth 
or mortality were not influenced by the frequency of hypoglycemia periods and the 
duration of the hyperglycemia episode and correction for these potential confounders 
was therefore not necessary.
Table 3. Characteristics of the hyperglycemia episode in all exposed infants.
N = 66 a Mean Minimum Maximum SD
Age at onset of hyperglycemia (days) 3.2 1 19 3.7
Number of hypoglycemia episodes 0.3 0 6 0.9
Mean glucose level (mmol/L) 12.9 10.1 21.9 2.3
Mean glucose intake (mg/kg/min) 6.3 3.4 11.0 1.3
Mean insulin infusion rate (U/kg/h) 0.06 0.01 0.34 0.06
Duration of hyperglycemia (hours) 34 12 169 25
Duration of insulin infusion (hours) 129 3 754 132
a Including deaths and infants lost to follow-up




A multivariable regression analysis on all very preterm infants admitted between 
January 2002 and December 2006 (n=798 infants with complete baseline 
characteristics), confirmed a significant increase in mortality in the exposed cohort 
(p = 0.001) (Table 4).
Subgroup analysis demonstrated that infants with a birth weight ≤1000 gram (mean 
gestational age 27.3 ± 1.8 weeks) and/or a gestational age of 24-28 weeks (mean 
birth weight 972 ± 229 gram) also had a significant relation between hyperglycemia 
and mortality. In the subgroup of infants with a birth weight >1000 gram (mean 
gestational age 30.1 ± 1.6 weeks) hyperglycemia was associated with an increased 
incidence of IVH (p = 0.025), severe RDS (p = 0.012) and sepsis (p = 0.002). Sepsis 
was also more prominent in a subgroup of infants with a gestational age of 29-32 
weeks (p = 0.009, mean birth weight 1503 ± 362 gram). In the regression analyses 
for morbidity and mortality statistical correction was done for gestational age, gender, 
birth weight, exposure to prenatal and postnatal steroids, presence of severe RDS, 
sepsis, PROM, chorioamnionitis, NEC, BPD, PVL and IVH. 
Table 4. Regression analysis for mortality in preterm infants.
Multivariate p-value
for hyperglycemia
Total population (N = 798a) 0.000
Gestational age subgroups
24-28 weeks (N = 265) 0.009
29-32 weeks (N = 533) 0.899
Birth weight subgroups
<1,000 gram (N = 188) 0.005
>1,000 gram (N = 610) 0.402
a 61 of the 859 very preterm infants had missing baseline characteristics and were excluded from the model
Discussion
The findings in this study indicate that hyperglycemia has no effect on long term 
growth. However, in addition to the already known short term effects, hyperglycemia 
has a distinct negative influence on neurological and behavioural outcome at 2 years 
of age. The observation by other investigators that hyperglycemia is a risk factor for 
early mortality in very preterm infants was confirmed. We found a firm association 
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between neonatal mortality and the mean and maximum glucose levels on days 3 and 
4 of the hyperglycemia episode. This association suggests that increased mortality is 
probably due to poorly controlled hyperglycemia. No association between mortality 
and duration of hyperglycemia was found. In subgroup-analyses we found relations 
between hyperglycemia and morbidity. Sepsis, severe RDS and IVH were more 
common in infants with hyperglycemia and a birth weight of >1000 gram (mean 
gestational age 30.1 ± 1.6 weeks).
Hays et al. demonstrated that blood glucose concentration had significant effects 
on both early death and the occurrence of severe IVH.7 To our knowledge, adverse 
neurological and behavioural outcome secondary to neonatal hyperglycemia has not 
been reported yet.
This retrospective study has several limitations. An observer-bias cannot be excluded 
because several physicians did the follow-up consults at the age of 2 year. To reduce 
the observer-bias as much as possible strict cut off points were made and the follow-up 
information was interpreted by only one person. In the future it would be interesting 
to do a prospective study, in which Bayley scores will be collected from all participants. 
Furthermore, it was quite difficult to match unexposed controls for date of admission 
within 1 year to reduce the influence of changing policies. The composition of the 
unexposed control group was randomly chosen and purely based on the in advance 
defined matching criteria. Nonetheless, unintentional selection cannot be excluded 
and the matched controls may not 100% represent the complete population of 
very preterm infants admitted to the nursery during the study period. An inevitable 
complicating factor in this study was the concomitant occurrence of hyperglycemia and 
insulin therapy, through which the individual influence of hyperglycemia or insulin 
therapy cannot be demonstrated. Although this study does not have the strength of a 
prospective follow-up study, the results will give some support and direction for the 
prognosis of the development of very preterm infants with hyperglycemia.
Treatment with insulin is not unequivocally associated with better outcome. The first 
study in adults by van den Berghe showed very promising results.15 However, it proved 
to be difficult to repeat the positive results in later studies in adults, and some studies 
even showed negative effects. Early treatment with insulin in preterm infants (without 
hyperglycemia) even showed higher mortality at 28 days in the early-insulin group 
than in the control group.14 The less favourable outcome in the insulin-treated group 
in this study could therefore also be due to the insulin therapy.
Several follow-up studies in infants with diabetes mellitus type 1 may explain our 
findings concerning neurobehavioural outcome. Infants with longer episodes of 




hyperglycemia seem to have an impaired cognitive development, though the specific 
impaired elements of cognitive development vary between the studies. Compared 
with healthy siblings, infants with hyperglycemia had a lower verbal intelligence.24 
A follow-up study conducted 2 years after the onset of type 1 diabetes suggests that 
hyperglycemia is associated with compromised learning- and consolidation capacities 
and organizational strategies. However, this follow-up study was repeated after another 
4 years, at which time this relationship could not be confirmed.25,26
Conclusion
The results of this retrospective follow-up study suggest that hyperglycemia and insulin 
therapy are not only associated with increased mortality and short term morbidity, but 
also exert long term effects on development. Given the definition of hyperglycemia, 
including the use of insulin for >12 hours, one can not assume that the association is 
due to poorly controlled hyperglycemia in this design, but may be the effect of insulin.
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General discussion




In this chapter we will discuss each “pearl” separately, provide short recommendations 
for best practice and future perspectives.
Lithium:  Fetal, neonatal and developmental outcomes of 
lithium-exposed pregnancies
Since 1970 lithium is registered by the Food and Drug Administration for treatment of 
acute manic episodes and as maintenance treatment for patients with bipolar disorders. 
Question rose about the safety of lithium during pregnancy for the developing fetus, as 
bipolar disorders are common in women of childbearing age.1 An international register 
of lithium babies, consisting of 225 infants exposed to lithium during pregnancy, 
reported an extremely increased risk (500-fold) for Ebstein’s anomaly. Ebstein’s 
anomaly is a very rare cardiac malformation with an incidence of 1:20.000 in normal 
pregnancies.2 Since that reported outcome, lithium was considered teratogenic and 
usage during pregnancy was highly dissuaded. Later case-control and cohort studies 
showed the 500-fold increased risk to be overestimated, due to a voluntary reporting 
bias of the lithium baby register. A causal relationship between intra-uterine lithium 
exposure and Ebstein’s anomaly could not be ruled out, as a general incidence of 
1:20.000 would require a very large study population, but other studies showed the 
expected increased risk to be maximal 28-fold.3-5
Slowly, lithium usage during pregnancy was reintroduced as the benefits of lithium 
continuation for maternal wellbeing became clear: discontinuation of lithium during 
pregnancy resulted in a 2-fold greater risk of recurrence of a new episode.6,7 In addition, 
prenatal and postpartum maternal illness can have negative consequences for later 
neurobehavioral outcome of the infant.8 Considering the small risk of teratogenic effects 
and the high risk of relapse after discontinuation of lithium during pregnancy, a balanced 
decision about optimal management should be made for each bipolar woman individually.
Crucial information on the long term neurobehavioral outcome of intra-uterine lithium 
exposure is scarce. Only one other study reported the follow-up of 60 infants, but 
this was performed with questionnaires, which created a considerable bias.9 The study 
in this thesis is the first follow-up study of lithium-babies performed by professionals 
using verified developmental scales. We found a normal neurobehavioral outcome in 15 
infants exposed to lithium in utero. The small group size and the lack of an appropriate 




control group are limitations and a much larger study population is necessary to draw 
more definite conclusions. While we are awaiting larger studies, these data can give 
counseling doctors and bipolar women more confidence in planning a safe pregnancy.
Recommendation
Teratogenicity of lithium is relatively limited and to date no evidence of impaired 
neurobehavioral outcome of offspring after intra-uterine lithium exposure has 
been reported. Therefore, we recommend continuation of lithium therapy during 
pregnancy in bipolar women who have until then benefited here from. Advantages and 
disadvantages of continuing lithium therapy during pregnancy should be precisely 
balanced for each bipolar woman individually.
Future perspectives
As lithium usage during pregnancy has slowly increased since the reports of less increased 
risk of teratogenicity from Jacobson and Zalstein, there must be large numbers of 
intra-uterine exposed infants.3,4 Psychiatric departments are still performing studies 
to determine the most optimal treatment strategy of bipolar women during pregnancy 
and include large numbers of mothers and infants.6,7,10 To gain more knowledge about 
the long term effects of intra-uterine lithium exposure it would be very helpful to 
add neonatal and long term follow-up evaluations to such relatively large psychiatric 
studies. As these mothers already consented for their own postpartum evaluation, 
they are probably also interested to consent for follow-up evaluation of their infant.
Importantly, future studies should include an adequate control group of infants from 
bipolar mothers who were not treated with lithium. As postpartum maternal illness 
can have influence on long term neurobehavioral development, comparison with 
control infants of non-bipolar mothers will not be reliable enough to demonstrate 
possible long term effects of intra-uterine lithium exposure.
Antenatal IVIG:  Neonatal outcome in allo-immune 
thrombocytopenia treated with 
antenatal intravenous immunoglobulin
The most common cause of severe thrombocytopenia in fetus and neonate is fetal and 
neonatal thrombocytopenia (FNAIT).11-13
Maternal immunization to paternally inherited antigens on fetal platelets causes 
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destruction of fetal platelets and severe fetal and neonatal thrombocytopenia. This 
disorder is comparable with red cell allo-immunization, but in contrast to that condition, 
FNAIT can also affect first pregnancies. Screening for FNAIT has not been realized 
yet, so the first child is frequently severely affected with severe thrombocytopenia and 
intracranial hemorrhage (ICH), which often occurs antenatally.14-16
Cornerstone for the management of pregnant women, allo-immunized in a previous 
pregnancy, is antenatal treatment with intravenous immunoglobulins (IVIG) or, in 
some centers, with additional steroids. There is a rising trend towards a more non-
invasive approach with minimization of fetal blood sampling, because the complication 
rate of this procedure (4.4-14% per pregnancy) is similar to or even higher than the 
risk for ICH in antenatally treated infants (0-10%).17-24 Effectiveness and safety of a 
(non-invasive) policy with maternal IVIG were confirmed by studies in our center by 
van den Akker et al. (2007) and in the study outlined in this thesis.21
Questions about the optimal dosage and the best age to start IVIG remain and require 
further investigation. In only one study dosage was varied from 1 g/kg to 2 g/kg 
maternal body weight, without clear benefits for one specific dose.23 Most studies 
about FNAIT report small groups and even smaller subgroups (sometimes varying in 
more than one study variable), making it difficult to draw firm conclusions. Because 
of this paucity of data, it is important to report all affected cases, as this may lead to a 
general international point of view and management can be based on a larger cohort 
of infants. Currently, a large international web-based registry of all FNAIT cases is 
active with antenatal IVIG dosages of 0.5 g/kg or 1.0 g/kg maternal body weight. This 
registry may shed more light on the optimal antenatal management in the near future.
In addition to optimizing therapy for already known affected cases of FNAIT, 
prevention of complications in first affected pregnancies is another important research 
topic. As HPA 1a incompatibility is responsible for 80-95% of the affected cases, 
screening for HPA 1a negative genotypes in all pregnant women is the first step in this 
process.17,18,21,23,25-27 However, only 8-12% of these HPA 1a negative women with fetal 
incompatibility will become immunized and produce allo-antibodies.27-32 Producing 
allo-antibodies is highly dependent on HLA type, e.g. HLA DRB3*0101 positivity 
is a poor predictor of becoming immunized, but has a high negative predictive value 
of 96-100%.27,28,32 Since there are still no clear factors to predict which immunized 
HPA 1a negative women are at greatest risk for delivering a severely affected neonate, 
antenatal screening is not practical yet. Some studies suggest use of the level of 
maternal antibody titer during pregnancy as a possible predicting factor, but data on 
its predictive value are conflicting and the diagnostic value is not clear.24,28,29





We recommend treatment of FNAIT according to a non-invasive protocol, with 
administration of antenatal IVIG starting at 16-18 weeks’ gestation in high risk 
pregnancies (i.e. those with ICH in an earlier sibling) and at 28 weeks‘ gestation in 
standard risk pregnancies. Our small study does not allow us to make a statement 
about an optimal dosage of IVIGs and gestational age to start, although in our cohort 
a dose of 0.5 g/kg in standard risk pregnancies and 1 g/kg maternal body weight in 
high risk pregnancies seemed effective in preventing ICH.
A matched platelet transfusion should be given if the platelet value at birth is <20 x 
109/L in non-bleeding and <50 x 109/L in bleeding infants. In case of an emergency 
(i.e. clinical bleeding) and no immediate availability of matched platelets, random 
platelets may be life-saving and recommended. When multiple matched platelet 
transfusions do not result in a sufficient rise in platelet value, treatment with IVIG 
should be considered. Neonatal platelet values need to be determined at least daily 
during the first days of life, until a spontaneous rise or stable level is observed.
Future perspectives
Future research should focus on finding usable predictive factors for a neonate 
with FNAIT in the first pregnancy, to prevent overtreatment of all immunized 
HPA 1a negative women and to treat only those pregnancies at highest risk for 
severe FNAIT. Only when useful predictive factors have been identified, antenatal 
screening and selective antenatal treatment may contribute to a reduction in long 
term neurodevelopmental morbidity due to ICH and will become a cost-effective 
intervention. More knowledge about optimal gestational age to start and dosing 
regimen of antenatal IVIG would be very valuable to optimize antenatal treatment of 
already known to be affected neonates with FNAIT. Addition of long term follow-up 
assessments to future studies, can give more insight in possible effects of antenatal 
IVIG on long term neurobehavioral outcome.
Ibuprofen:  Repeated courses of ibuprofen are effective 
in closure of a patent ductus arteriosus.
Closure of the ductus arteriosus in term infants normally occurs within 48-72 hours 
after birth, stimulated by an increase of arterial pO2 and decrease of circulating 
vasodilating prostaglandins. In preterm infants the ductus arteriosus frequently fails 
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to close or remain closed, with an incidence of 55-70% in those with a gestational 
age of <29 weeks or a birth weight of <1000 gram. The premature ductus arteriosus 
has a higher sensitivity for circulating vasodilating factors, such as nitric oxide and 
prostaglandins, and limits vasoconstriction, hypoxia, ischemia and the process of 
changing into a non-contractile ligament.33-36
Patency of the ductus arteriosus (PDA) was associated with increased morbidity and 
mortality and this led in the mid 1970s to a search for adequate treatment opportunities. 
Based on a few small randomized controlled trials, reporting improvement of lung 
compliance, shorter duration of mechanical ventilation and shorter need for oxygen 
after surgical or pharmacological ductal closure, the main goal of management became 
closure of a hemodynamic significant PDA.37-43 Since that time, a multitude of studies 
to detect the most optimal treatment strategy for PDA closure have been performed: 
fluid restriction, non-steroidal anti-inflammatory drugs (NSAIDs) which selectively 
inhibit cyclooxygenase and the formation of prostanoids from arachidonic acid (COX 
inhibitors such as indomethacin and ibuprofen), indomethacin versus ibuprofen, 
prophylactic versus symptomatic approach, pharmacological versus surgical closure, 
oral versus intravenous ibuprofen and studies to determine the most optimal dosing 
regimen for pharmacological closure.
However, in contrast to the short term effects on lung function, effects of ductal 
closure on general neonatal morbidity and neurodevelopmental outcome were 
only sporadically investigated. Associations of PDA with NEC and chronic lung 
disease were confirmed in recent studies, but causality was never proven and these 
complications occurred despite ductal closure.44-49 Although a delay of surgical closure 
of >21 days results in a longer duration of mechanical ventilation and higher oxygen 
need, long term outcome such as chronic lung disease has not been reported.50 A 
prophylactic indomethacin protocol prevented severe IVH, but did not influence 
neurodevelopmental outcome at follow-up.51 Mortality is the only concrete outcome 
measure in which the benefit of ductal closure seems clear, with an odds ratio of 8 for 
preterm infants with failure of ductal closure.52
Since neonatal health care developed and improved drastically in the last 30 years 
(including the introduction of antenatal steroids and surfactant usage), some authors 
doubt the advantages of ductal closure and treatment preferences of PDA are again 
a hot topic. The fundamental idea that closure of a hemodynamic significant PDA is 
preferable is based on evidence of more than three decades ago, but it is questionable if 
our current population of preterm infants is comparable with the nursery population of 




30 years ago. Vanhaesebrouck et al investigated a conservative approach with increase 
in mechanical ventilation conditions (PEEP) and decrease in daily fluid intake and 
found a high rate of spontaneous ductal closure. However, this study lacks data on 
the duration of spontaneous ductal closure, long term morbidity and consequences 
of a possible longer duration until ductal closure. 53 Others suggest to investigate 
symptomatic treatment of PDA, instead of focusing on ductal closure.54
A main problem in the quest to prove the possible disadvantages of ductal closure (or 
confirm the earlier reported benefits) is the difficulty to design an ethically justified 
randomized controlled trial, in which half of the PDA’s will be closed and the other 
half will remain open. Such a RCT should include long term follow-up to assess 
neurodevelopmental outcome and long term consequences of neonatal morbidities 
such as chronic lung disease, NEC, and ROP.
Until there is evidence to demonstrate that it is better to leave a PDA untreated, 
studies striving for optimization of ductal closure, like the study reported in this 
thesis, remain necessary. We found an acceptable closure rate of PDA after a second 
and even third course of ibuprofen, without additional adverse effects. Based on these 
results we prefer a third course of ibuprofen, after a failed second course, above possible 
harmful surgical closure. 
Recommendation
Our current treatment policy is still focused on closure of the hemodynamic significant 
PDA because no disadvantages of closure have been demonstrated. Our retrospective 
study demonstrated that second and third courses of ibuprofen, in an attempt to close 
the ductus, were effective and safe. We therefore prefer multiple courses of ibuprofen 
above possible harmful surgical closure.
Future perspectives
Partially based on our results, the most realistic design to gain more knowledge about 
the advantages and disadvantages of ductal closure (without performing a RCT) is a 
large scale prospective study. In this study all preterm infants with a hemodynamic 
significant PDA should be initially treated with ibuprofen, up to three courses if 
necessary. Data about mortality, morbidity, long term neurobehavioral development 
and long term consequences of neonatal morbidities should be collected prospectively. 
These outcomes should then be correlated with the duration of the PDA. Recently, 
two case-series of preterm infants treated with paracetamol for PDA (because of COX-
inhibitor resistance or contra-indications) were published, with surprising closure 
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rates. Larger studies of paracetamol treated infants are needed to analyze effects and 
side effects of this treatment.55,56 Another upcoming issue is the usage of oral instead 
of intravenous ibuprofen as cheap alternative. Also for this treatment approach more 
large studies are necessary to confirm the efficacy and especially the safety of oral 
ibuprofen, before considering this as treatment of first choice.57-59
Rifampin:  Use of rifampin in persistent coagulase 
negative staphylococcal bacteremia in 
neonates
Late onset sepsis (i.e. >72 hours after birth) is a common problem in Neonatal Intensive 
Care Units and is mainly caused by coagulase negative staphylococci (CoNS), which 
are considered to be minimal virulent pathogens. CoNS are skin commensals and 
are therefore often seen as contaminants in blood cultures. However, their presence 
on the skin facilitates entry into the body through indwelling catheters, which are an 
important risk factor for CoNS bacteremia and may present with serious illness with 
clinical sepsis and instability.83-87
Among infants with CoNS bacteremia 12-40% develops persistent CoNS bacteremia, 
which is in most studies defined as at least 3 positive blood cultures with the same 
species despite antimicrobial treatment drawn at intervals of at least 48 hours.88-91 
Risk factors for persistent CoNS bacteremia are low birth weight, low gestational 
age, low absolute neutrophil count (<1000 cells/µL), parenteral feeding and receiving 
artificial instead of breast feeding. A relationship with the persistence and presence 
of indwelling catheters remains doubtful, as some studies confirm and others deny 
this relationship.88,90-93 Short term outcome of persistent CoNS bacteremia includes 
an increased incidence of neonatal hyperglycemia, endocarditis and higher creatinine 
levels (possibly due to longer duration of vancomycin treatment), but neonatal 
mortality does not increase due to persistence.89-93 In the long term, persistent CoNS 
bacteremia is associated with longer hospitalization and chronic lung disease (O2 need 
at 36 weeks postmenstrual age).93
The incidence of late onset sepsis in preterm infants is increasing, possibly due 
to increased survival of very preterm infants and increased usage of indwelling 
catheters.83,84 The incidence of persistent CoNS bacteremia is also increasing, with 
higher minimal inhibitory concentrations (MIC) of vancomycin to provide adequate 
treatment of CoNS bacteremia as well.91,93 The cause of this increased incidence 




and decreased susceptibility for vancomycin is not totally clear yet. Most likely it’s a 
complicated process of changes in virulence of the CoNS species, colonization of the 
NICUs and the admission of more extreme preterm infants. An important bacterial 
virulence factor is biofilm production, which is more common in persistent compared 
to non-persistent CoNS isolates. These biofilm producing CoNS isolates (especially 
S. epidermidis) have increased MIC values and resistance to many antimicrobials. 
Another consequence of biofilm production is a reduced access of antimicrobials 
through indwelling catheters.90,94-96 Hypothetically, an increase in biofilm producing 
CoNS species that colonize our NICU’s could be explain the changes in epidemiology. 
However, the studies reporting an increased incidence of persistent CoNS bacteremia 
do not report the biofilm production of their isolates. In addition, some studies have 
shown that bacteremia persists after removal of indwelling catheters, suggesting that 
other factors than biofilm are also responsible for persistence.89,91 
Although the complete causal pathway leading to an increasing incidence 
of persistent CoNS bacteremia is not clear yet, we have to deal with this 
serious health problem in neonatal health care. Several studies in adults have 
confirmed the additional value of rifampin to antimicrobial treatment.97-101 
In neonates only 16 clinical cases (and 21 cases in a pharmacological analysis) 
were reported before we studied a series of 18 neonates, outlined in this thesis. We 
confirmed the additive effect of rifampin to vancomycin treatment for persistent 
CoNS bacteremia, with sterilization of blood culture within 2.3 ± 1.6 days and a 
considerable decline of C-reactive protein (CRP), especially in the first 3 days of 
rifampin treatment. However, special attention should be paid to optimization of 
vancomycin treatment by monitoring blood levels.
Recommendation
Based on current evidence we recommend vancomycin monotherapy when CoNS, 
susceptible for vancomycin, are isolated from a blood culture. Vancomycin trough and 
peak serum levels should be precisely monitored to optimize treatment. Indwelling 
catheters should be removed when blood culture becomes positive, but only if the 
clinical condition of the neonate does allow this. When bacteremia persists for at least 
6 days, with 3 positive blood cultures (with 48 hours intervals), we recommend adding 
rifampin therapy to vancomycin. In addition, echocardiography and an ultrasound 
of the large abdominal vessels should be done to exclude an intravascular thrombus 
as cause of the persisting bacteremia.




To gain more knowledge about the changing epidemiology of late onset sepsis caused 
by CoNS, we need a prospective study with a large cohort of infants with non-
persistent and persistent CoNS bacteremia, describing clinical as well as microbial and 
pharmacological details. In addition, it would be very valuable to compare duration 
of bacteremia with and without rifampin addition, in a placebo-controlled double 
blind randomized controlled trial. As persistent CoNS bacteremia is associated with 
neonatal morbidity on short term and chronic lung disease on long term, investigation 
of neurobehavioral outcome on long term is desirable.
Postnatal IVIG:  Outcome and management in neonatal 
thrombocytopenia due to maternal ITP
The incidence of idiopathic thrombocytopenic purpura (ITP), also known as auto-
immune thrombocytopenia, in pregnant women is 1-10:10.000. Maternal anti-platelet 
antibodies, especially against GPIIb/IIIa platelet proteins on the cell membranes of all 
platelets, cause maternal thrombocytopenia and can pass via the placenta to the fetus.60-63
Surprisingly, severe neonatal thrombocytopenia (<50x109/L) is present in only 8-13% 
of the neonates. Unlike the earlier in this thesis described condition of fetal and 
neonatal allo-immune thrombocytopenia, severe bleeding complications (i.e. ICH) 
are very rare in neonates born from mothers with ITP with an incidence of 0-2.9%.64-72
The nadir of neonatal platelets is mostly seen around postnatal days 3-5; an explanation 
for this relatively late nadir is not clear yet.61,69,73-75 Koyama et al reported an increased 
risk for severe neonatal thrombocytopenia in neonates delivered vaginally, suggesting 
an additional antibody boost passing the placenta due to uterine contractions. 
Hypothetically, this could be the reason for the relatively late nadir, but the late nadir 
for infants born by elective cesarean section can not be declared with this hypothesis. 
As the nadir of neonatal platelets is postpartum instead of antenatal, risk of intrauterine 
or peripartum ICH is less prominent. This is confirmed by a total reported rate of 
intrauterine ICH of 5/23 (22%) of all reported ICHs in neonates from mothers 
with ITP.70,76 As peripartum ICH has never been reported, the method of delivery is 
nowadays only determined by obstetrical indications.70,72
Several retrospective studies describe possible predicting factors for severe neonatal 
thrombocytopenia, only maternal splenectomy and delivery of a previous 
infant with severe thrombocytopenia were associated with an increased risk for 




thrombocytopenia.65,66,69-72,77,78 Evidence is conflicting, but in most large studies 
maternal platelet counts (during pregnancy and delivery), maternal antibody 
state and maternal ITP treatment were not associated with severe neonatal 
thrombocytopenia.64,64,66,68,69,71,72,77,79 As antenatal treatment with IVIG seems to 
prevent ICH in FNAIT without an associated increase in neonatal platelets (chapter 
3 in this thesis), this mechanism is perhaps also active in maternal IVIG treatment 
for ITP. However, this is difficult to prove, because the incidence of ICH is very low 
in neonates from mothers with ITP during pregnancy.
Considering the extremely small risk of intrauterine or peripartum ICH, one may 
wonder about the clinical importance of determining risk factors for severe neonatal 
thrombocytopenia. As the neonatal platelet nadir is on postnatal day 3-5, the 
greatest bleeding risk is at that moment. Therefore, it makes more sense to focus on 
optimization of postnatal management, instead of determining possible risk factors. 
The majority of retrospective studies only appoint the number of infants which receive 
the different kinds of treatment, without analyzing the effectiveness of each separate 
treatment, possible due to the small amounts of severely affected infants.62,65-67,79,80 
Only 2 studies described a relatively large cohort of infants recommending one specific 
treatment: Ballin et al described 11 infants receiving postnatal IVIGs after platelet 
transfusions and Ovali et al described 6 neonates receiving prednisone after failed 
postnatal IVIGs. Ballin et al, however, did not analyze the increments after platelet 
transfusions and IVIG in detail; the effect of prednisone in the study of Ovali et al is 
dubious as all infants received IVIG prior to prednisone, which is known to take time 
before becoming effective.81,82 The study described in this thesis is the first to analyze 
the course of postnatal platelet values and treatment effects of platelet transfusions 
and IVIG of each neonate with severe thrombocytopenia individually. We found a 
substantial relapse rate after multiple platelet transfusions without IVIG, but IVIG 
did not rule out relapse either. When relapse was occurring during IVIG treatment, 
this was most likely caused by the fact that IVIG needs a couple of days before 
becoming effective.
Recommendation
We recommend checking platelet values from umbilical cord blood, followed by daily 
platelet counts until postnatal day 5 or until a spontaneous rise (or stable level) is 
observed. If platelets are <50 x 109/L, a cranial ultrasound scan should be made 
to rule out ICH. Treatment with platelet transfusions is indicated in case of severe 
thrombocytopenia (<50 x 109/L); in case of relapse after the first platelet transfusion 
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we recommend to add IVIG. When thrombocytopenia persists and does not resolve 
after treatment with IVIG and multiple platelet transfusions, prednisone therapy can 
be considered. 
Future perspectives
A randomized controlled trial for optimization of postnatal management of severe 
neonatal thrombocytopenia due to maternal ITP was never done and would be 
extremely difficult to perform because of the rarity of the condition. An international 
prospective registry of all infants with severe neonatal thrombocytopenia due to 
maternal ITP, containing details about their treatment and platelet course over time, 
would be very valuable to gain more knowledge for optimization of postnatal therapy. 
Such prospective registry can be completed with a follow-up assessment on long term, 
to consider possible effects of antenatal and postnatal IVIG and/or prednisone on long 
term neurobehavioral outcome.
Insulin:  Short and long term outcome of neonatal 
hyperglycemia in very preterm infants
Hyperglycemia in preterm infants is caused by a complicated pathway including 
a combination of insulin resistance and relative insulin deficiency. Due to high 
circulating levels of inflammatory markers, cytokines and catecholamines resistance 
to insulin develops, with minimal glucose absorption for storage and no inhibition of 
gluconeogenesis by the liver. The immature pancreatic β-cells aren’t able to compensate 
for these high glucose levels, as they can almost only produce pro-insulin, which is 
a 10-fold less active precursor of insulin, leading to relative insulin deficiency.102-104
Reported incidence of hyperglycemia in preterm infants is variable, as gestational ages 
differ between studies and there’s still no consensus about a strict cut-off value for a 
widely used definition of hyperglycemia. In neonates with a birth weight of <1500 
grams incidence of hyperglycemia varies between 36 and 68%.105-108
Hyperglycemia is associated with increased neonatal mortality.107-111 ROP, NEC 
and cerebral white matter damage are also more common in preterm infants with 
hyperglycemia.108,109,111-114 A relationship between hyperglycemia and IVH was only 
established in subgroup-analyses in hyperglycemic preterm infants and in an old 
study not correcting for confounding factors. Another frequently cited article for 
the relationship between IVH and hyperglycemia, of Finberg et al, only suggested 




a relationship based on the pathophysiological pathway of hyperosmolality leading 
to intracranial hemorrhage, but didn’t describe a population of preterm infants with 
evidence for this relationship.110,115-117
In many centers restriction of glucose intake is the first step in treatment of 
hyperglycemia. However, adequate caloric intake and weight gain in the first weeks 
of life are essential for later growth and neurobehavioral development.118-120 Therefore, 
restriction of glucose intake must be limited to ensure a minimum intake to avoid 
malnutrition. Since the early eighties continuous insulin infusion is used to control 
excessive glucose levels. Advantages of insulin compared to the earlier used glucose 
restriction policy were less sepsis, higher glucose intake, better growth and more daily 
weight gain. 121-124
In pediatric and adult intensive care units tight glucose control seems to reduce 
morbidity and mortality. This positive effect of tight glucose control in the older 
intensive care population, led to the hypothesis that this might also be applicable 
for preterm infants with hyperglycemia.125-127 Beardsall et al studied an early elective 
insulin strategy (with prophylactic insulin from the first day of life), leading to a 
better energy intake, increased lower leg length and less episodes of hyperglycemia. 
However, mortality at postnatal day 28 and the incidence of hypoglycemic episodes 
were significantly higher with this early elective insulin policy.105,128 The use of tight 
glycemic control, without prophylactic insulin, was also associated with an increased 
risk for hypoglycemia.129 Recurrent or prolonged episodes of hypoglycemia are 
associated with cerebral damage, especially in parietal and occipital white matter and 
cortex, leading to an impaired neurodevelopmental outcome.130-132 The advantages of 
insulin treatment for hyperglycemia need therefore to be balanced against the risks 
of hypoglycemia.
The only study on long term outcome of hyperglycemia in preterm infants was 
retrospective and performed by ourselves (outlined in this thesis). We found an 
impairment of both neurological and behavioral outcome in preterm infants with 
hyperglycemia, compared to those without. However, all infants received insulin 
treatment, which obfuscates the possible beneficial effects of insulin for neurobehavioral 
outcome. Did our infants have an impaired neurobehavioral outcome because of 
hyperglycemia induced brain damage or was this due to insulin usage with the 
possibility of undetected episodes of hypoglycemia?110,133 Unfortunately, above 
mentioned associations of hyperglycemia with increased mortality and short term 
morbidity were only reported in study groups who also received insulin.
We concluded that hyperglycemia in preterm infants is associated with neonatal 
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mortality, short term morbidities and long term impaired neurobehavioral outcome. 
Despite the ability of insulin to lower serum glucose levels, beneficial effects in 
reduction of mortality, morbidity and impairment of neurobehavioral outcome have 
never been shown.
Recommendation
The real benefits of insulin treatment for hyperglycemia in preterm infants are not 
clear yet. This is due to the lack of comparisons of mortality, short term morbidity 
and long term outcomes in infants treated with and without insulin. Until specific 
advantages or disadvantages are proven, we recommend using insulin to control 
extreme glucose values. It is pivotal to strictly monitor glucose levels to prevent 
episodes of hypoglycemia during insulin administration.
Future perspectives
Comparison of prospectively collected data about mortality, short term morbidities 
and long term neurobehavioral outcome of preterm infants with hyperglycemia, treated 
with and without insulin, is necessary to detect the real advantages (or disadvantages) 
of insulin use. It would be helpful to obtain a uniform glucose cut-off value beyond 
which hyperglycemia has harmful effects and insulin treatment should be started.
Main conclusion
The aim of this thesis was to emphasize the clinical importance of retrospective research 
and the necessity of regular evaluations of currently used treatment protocols. All 
neonatal pearls described in this thesis were based on practical and clinical questions 
about currently used protocols; each study contains clinically relevant and usable 
recommendations for daily medical practice. Despite their retrospective character, 
which is not the design to gain the strongest evidence, these pearls are very important 
for neonatal medical health care.
Rare diseases will always be there, health care opportunities will be expanding and 
populations will continue to change: for these reasons we should continue to reflect 
on our medical handling and adapt and improve our policies. The chain of neonatal 
pearls should therefore remain open for new reflecting pearls, so beading can proceed 
in future.
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Chapter 1 - General introduction.
Neonatal health care is provided with medication and protocols for almost all 
morbidities. Before the use of these medicines is allowed, they are extensively studied 
and tested for efficacy and safety. As patient population and knowledge on specific 
diseases changes with time, repeated evaluation of efficacy and safety of current 
used policies is of paramount importance. The most suitable study design for such 
evaluations is a retrospective overview, through which incidence and accompanying 
comorbidity can be surveyed. Results can possibly lead  to adjustments of the protocol 
or be an incentive for new randomized controlled trials (RCT). RCTs are, however, 
only ethically justified once retrospective evidence is sufficient to  suggest advantages 
of a possible new intervention.
Another great benefit of retrospective studies is their usefulness in investigation of 
rare diseases, which are common in neonatology. Designing prospective studies for 
possible new interventions in rare conditions, is extremely difficult.
Both above named reasons make retrospective studies indispensable in medical 
research.
In this thesis six ‘Neonatal Pearls’ are presented: six relatively rare clinical conditions, of 
which a retrospective study evaluates the efficacy, safety and/or long term consequences 
of the current protocol. Despite their retrospective design and relatively small sample 
size, they are all of significant value and may serve as potential foundations for future 
protocol adjustments and randomized controlled trials.
The general aim of this thesis was to emphasize the importance retrospective studies 
and evaluation of already existing protocols. Six retrospective studies investigating 
effectiveness, safety and/or long term consequences of different medicines in neonates 
are described.
Chapter 2 –  Fetal, neonatal and developmental outcomes of 
lithium-exposed pregnancies.
Many women with a bipolar disorder are of reproductive age and will need to continue 
lithium treatment during pregnancy, as risks for relapses are high when discontinuing 




lithium. The teratogenic and perinatal effects of lithium are slightly known, in 
contrary to the long-term effects of lithium on neurodevelopmental outcome of these 
children. In chapter 2 we investigated growth, neurological, cognitive and behavioral 
development of children exposed to lithium in utero in an observational retrospective 
cohort study. Of the 30 infants who were exposed to lithium in utero, 15 were available 
for follow-up and were investigated at 3-15 years of age. Only one child had signs of a 
minor neurological dysfunction, but without further clinical implications. Cognitive 
tests scores were within normal limits, although most children had lower scores on 
the performance IQ subtest. Growth, behavior and general development were all 
within the normal range. According to our results continuing lithium therapy during 
pregnancy seems not to cause adverse effects on growth, neurological, cognitive and 
behavioral development of exposed children.
Chapter 3 –  Favorable neonatal outcome in allo-immune 
thrombocytopenia treated with antenatal intravenous 
immunoglobulin.
Fetal and neonatal allo-immune thrombocytopenia (FNAIT) is the most common 
cause of severe thrombocytopenia in neonates. Weekly maternal intravenous 
immunoglobulins (IVIG) is the cornerstone in antenatal treatment for already known 
cases of FNAIT. Nowadays, most centers prefer a non-invasive approach without fetal 
blood sampling (FBS) and intra-uterine platelet transfusions (IUPT). In chapter 3 we 
described a retrospective overview of 23 neonates treated antenatally between January 
2006 and January 2012 with weekly maternal administration of IVIG. Twelve neonates 
(52%) had platelet counts <50 x 109/L, of which 3 had spontaneous rise, 8 received 1 
matched platelet transfusion and 1 needed 2 matched transfusions. Three neonates had 
petechiae and hematomas, without clinical consequences. Only 1 neonate, without a 
sibling with intracranial hemorrhage (standard risk), had an intracranial (ICH) just 
before the start of antenatal IVIG at 28 weeks. Neurodevelopmental follow-up at two 
years of age was normal. The results of this study suggest that antenatal treatment with 
weekly maternal IVIG and postnatal matched platelet transfusion are effective and 
safe for the management of FNAIT.
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Chapter 4 –  Repeated courses of ibuprofen are effective in closure 
of a patent ductus arteriosus.
Patent ductus arteriosus (PDA) is a frequent complication in preterm infants. 
Ibuprofen and indomethacin (both COX-inhibitors) are used for pharmacological 
closure of PDA. In most centers a failed second course of COX-inhibitors is followed 
by possible harmful surgical closure. In chapter 4 we described a retrospective study 
to estimate the closure rate of clinically significant PDA after second and third courses 
of ibuprofen and record possible side effects. A total of 164 preterm infants, admitted 
between November 2005 and September 2011, with PDA were included. The closure 
rate was similar after the first (109/164), second (24/43) and third (6/11) course of 
ibuprofen (X2=2.1, p=0.350). Late start of the first course of ibuprofen was a predictive 
factor for increased need of a second course (X2=4.4, p=0.036). No additional side 
effects of multiple courses of ibuprofen were detected. Based on this study we conclude 
that repeated courses of ibuprofen are an effective and safe alternative for surgical 
closure and should be considered after failure of the first course of ibuprofen
Chapter 5 –  Use of rifampin in persistent coagulase negative 
staphylococcal bacteremia in neonates.
Coagulase negative staphylococci (CoNS) are the most common cause of late onset 
sepsis in the Neonatal Intensive Care Unit (NICU). A minority of neonates does not 
respond to vancomycin therapy and develops persistent bacteremia, which may be 
treated with rifampin (originally an antibiotic against the tubercle bacillus). In chapter 5 
we evaluated the use of rifampin in persistent CoNS bacteremia with a retrospective 
study of 137 neonates with CoNS bacteremia. Eighteen of these neonates were treated 
with rifampin, because of persistent bacteremia (3 positive blood cultures at least 48 
hours apart with clinical symptoms) or (suspected) intravascular thrombus. Duration 
of bacteremia prior to rifampin therapy (8.0 ± 3.6 days) was positively correlated to 
the total duration of bacteremia (10.3 ± 3.7 days). The earlier rifampin was started, 
the earlier the blood culture became sterile. After starting rifampin therapy C-reactive 
protein (CRP) levels of all neonates declined and blood cultures became sterile after 
2.3 ± 1.6 days. Vancomycin levels were not consistently measured in all neonates, 
sometimes resulting in late detection of sub-therapeutic trough levels. The results 
of this study indicate that rifampin is effective in the treatment of persistent CoNS 




infections in neonates, but outcome may be more improved by adequate monitoring 
of vancomycin trough levels.
Chapter 6 –  Outcome and management in neonatal 
thrombocytopenia due to maternal ITP.
Neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura 
(ITP) is not uncommon, but ICH is very rare(<1%). Postnatal neonatal treatment consists 
of platelet transfusions, IVIG and/or prednisone; however evidence about the preferred 
postnatal treatment is scarce. In chapter 6 we described a retrospective analysis of the 67 
neonates born from 41 mothers with ITP during pregnancy. Severe thrombocytopenia 
occurred in 20/67 (29.9%) neonates; in one neonate unilateral polymycrogyria was 
detected on cranial imaging. In 3 neonates platelet count rose spontaneously, whereas 18 
neonates received treatment (of which 1 due to persistent moderate thrombocytopenia). 
Postnatal treatment consisted of: platelet transfusions (n=3), prednisone (n=2), IVIG 
(n=1), platelet transfusions and IVIG (n=11), platelet transfusion and prednisone (n=1). 
Relapses of platelet counts after platelet transfusions were commonly seen. Risk factors 
for severe neonatal thrombocytopenia were delivery of a previous neonate with severe 
thrombocytopenia and low maternal platelet nadir during pregnancy.
The results of this study suggest severe thrombocytopenia in neonates from mothers 
with ITP occurs more frequently than previously reported. Treatment with multiple 
platelet transfusions and IVIG is often  required to reach a platelet count above 
50x109/L. We propose starting IVIG, when platelet count falls quickly below 50 x 
109/L after the first platelet transfusion. 
Chapter 7 –  Short and long term outcome of neonatal 
hyperglycemia in very preterm infants.
Hyperglycemia in preterm infants is associated with increased morbidity and 
mortality, but data on long-term outcome are limited. In chapter 7 we investigated 
the effects of neonatal hyperglycemia (blood glucose >10 mmol/l, treated with 
insulin for >12 hours) on growth and neurobehavioral outcome at 2 years of age in a 
retrospective follow-up study. Between January 2002 and December 2006 859 preterm 
infants (<32 weeks) were admitted, of which 66 (8%) developed hyperglycemia. 
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Hyperglycemia was significantly correlated to mortality, with 27/66 (41%) in the 
hyperglycemia group versus 62/793 (8%) in those without hyperglycemia. Mortality 
was predominantly observed in hyperglycemic infants with mean glucose values > 8.0 
mmol/L or maximum glucose values > 9.5 mmol/L on days 3-4 after the diagnosis of 
hyperglycemia. Morbidity was also more common in infants with hyperglycemia and 
a birth weight of <1000 gram or a gestational age below 28 weeks. 
Thirty-three survivors treated with insulin for hyperglycemia and 63 controls 
(matched for gestational age, birth weight, gender and year of admission) without 
hyperglycemia were evaluated for follow-up at a corrected age of 2 years. Growth 
was similar, but behavioral and neurological development were more frequently 
abnormal among those with hyperglycemia. We concluded that despite treatment 
with insulin, hyperglycemia has negative effects on mortality and neurobehavioral 
outcome. Therefore, more research to the pathophysiology of hyperglycemia-induced 
brain injury should be performed and better strategies to manage hyperglycemia are 
urgently required.
Chapter 8 – General discussion.
In the general discussion, the main results of this thesis were discussed for each 
chapter separately. A summary on ‘what is already known’ of each topic was given, 
underlining the weaknesses and contradictions in current evidence. Suggestions for 
further research were done, to improve our knowledge for optimization of treatment 
policies. Practical recommendations based on the current evidence, in combination 
with the results of the studies described in this thesis are proposed. We conclude 
by stating that evaluation and adjustment of medical interventions in neonates is a 
continuous process, which requires increased awareness from the medical community 
and well-designed studies.
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Hoofdstuk 1 – Algemene introductie.
De neonatale gezondheidszorg is vandaag de dag voorzien van medicatie en protocollen 
voor bijna alle ziektes. Voordat deze medicijnen officieel gebruikt mogen worden, 
worden ze uitgebreid onderzocht op effectiviteit en veiligheid. Aangezien patiënt 
populaties en kennis over specifieke ziektes veranderen in de loop van de tijd, is het erg 
belangrijk effectiviteit en veiligheid te blijven evalueren. Een retrospectief overzicht 
is het meest geschikt voor zulke evaluaties, waardoor incidentie en co-morbiditeit 
duidelijk wordt. Uitkomsten kunnen daarna leidend zijn voor aanpassingen van 
bestaande protocollen of nieuwe gerandomiseerde trials. Deze gerandomiseerde trials 
zijn echter alleen ethisch verantwoord, als er voldoende retrospectieve aanwijzingen 
zijn om de voordelen van de nieuwe interventie te bewijzen.
Een ander groot voordeel van retrospectieve studies, is de bruikbaarheid voor 
het onderzoeken van zeldzame aandoeningen, die relatief veel voorkomen in de 
neonatologie. Voor deze aandoeningen is het heel moeilijk prospectieve studies uit te 
voeren, waardoor het extra belangrijk is alle aangedane cases te rapporteren.
Beide bovengenoemde toepassingen maken retrospectieve studies onmisbaar in de 
medische wetenschap. In dit proefschrift worden zes ‘Neonatale parels’ gepresenteerd: 
zes relatief zeldzame klinische condities, waarvan met behulp van een retrospectieve 
studie effectiviteit, veiligheid en/of lange termijn gevolgen van het huidige 
medicamenteuze protocol worden geëvalueerd. Ondanks hun retrospectieve karakter 
en de relatief kleine onderzoeksgroepen, zijn al deze zes parels van grote waarde als 
basis voor toekomstige protocolverbeteringen of grotere gerandomiseerde studies.
Het belangrijkste doel van dit proefschrift was het belang van retrospectieve studies en 
evaluatie van huidige gebruikte protocollen te benadrukken. Zes retrospectieve studies 
beschrijven de evaluatie van veiligheid, effectiviteit en/of lange termijn uitkomst van 
medicatie voor foetus en neonaat.
Hoofdstuk 2 –  Korte en lange termijn uitkomsten van kinderen, 
blootgesteld aan lithium tijdens de zwangerschap.
Veel vrouwen met een bipolaire stoornis zijn in de vruchtbare periode van hun leven 
en moeten de behandeling met lithium continueren tijdens de zwangerschap, omdat 
het risico op een terugval direct na de zwangerschap bij staken erg groot is. De 
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teratogene en perinatale effecten van lithium op de foetus en neonaat zijn enigszins 
bekend, in tegenstelling tot de lange termijn effecten van intra-uteriene lithium 
blootstelling. In hoofdstuk 2 onderzochten we de groei, neurologische, cognitieve en 
gedragsmatige ontwikkeling van kinderen die tijdens de zwangerschap blootgesteld 
werden aan lithium, in een observationele retrospectieve cohort studie. Vijftien van 
de 30 (50%) kinderen, die blootgesteld werden aan lithium tijdens de zwangerschap, 
waren beschikbaar voor follow-up onderzoek op een leeftijd van 3-15 jaar. Slechts 1 
kind had tekenen van milde neurologische afwijkingen, maar zonder verdere klinische 
gevolgen. Cognitieve testen waren binnen de normaalwaarden, wél hadden de meeste 
kinderen lagere scores op performance IQ testen. Groei, gedragsmatige- en algemene 
ontwikkeling waren binnen de normaalwaarden. Op basis van deze resultaten lijkt 
het continueren van lithium gedurende de zwangerschap geen duidelijke nadelige 
effecten te hebben op groei, neurologische, cognitieve en gedragsmatige ontwikkeling 
van intra-uterien blootgestelde kinderen.
Hoofdstuk 3 –  Goede neonatale uitkomst in allo-immune 
thrombocytopenie, behandeld met antenatale 
intraveneuze immunoglobulines.
Foetale en neonatale allo-immuun trombocytopenie (FNAIT) is de meest voorkomende 
oorzaak van ernstige trombocytopenie bij neonaten. Wekelijkse maternale behandeling 
met intraveneuze immunoglobulines (IVIG) is de basis van de behandeling van bekende 
gevallen van FNAIT. De meeste centra prefereren een niet-invasieve benadering 
zonder foetale bloedafname en intra-uteriene trombocytentransfusies. In hoofdstuk 
3 beschreven we een retrospectieve studie van 23 antenataal behandelde neonaten 
tussen januari 2006 en januari 2012. Twaalf neonaten (52%) hadden trombocyten 
van <50 x 109/L bij de geboorte, waarvan er 3 een spontane stijging hadden. Acht 
neonaten kregen 1 gematchte trombocytentransfusie, 1 neonaat had 2 gematchte 
trombocytentransfusies nodig voor een adequate stijging in trombocytengetal. Drie 
neonaten hadden petechiën en hematomen, zonder klinische consequenties. Slechts 
1 neonaat, zonder broertje of zusje met een intracraniële bloeding (standaard risico 
zwangerschap), had een intracraniële bloeding vlak voor de start van antenatale 
IVIG bij een amenorroeduur van 28 weken. Follow-up op de leeftijd van 2 jaar 
was niet afwijkend. De resultaten van deze studie suggereren dat antenatale 
behandeling met wekelijks maternale IVIG en postnatale behandeling met gematchte 
trombocytentransfusies effectief en veilig zijn in de behandeling van FNAIT.
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Hoofdstuk 4 –  Meerdere ibuprofen kuren zijn effectief voor het 
sluiten van een persisterende ductus arteriosus.
Een persisterende ductus arteriosus (PDA) is een veel voorkomende complicatie bij 
prematuren. Ibuprofen en indomethacin (beiden COX-remmers) worden gebruikt 
voor farmacologische sluiting van de ductus arteriosus. In de meeste centra wordt 
een falende tweede kuur COX-remmers gevolgd door chirurgische sluiting, wat 
geassocieerd is met morbiditeit en een slechtere ontwikkeling. In hoofdstuk 4 
beschreven we een retrospectieve studie die het sluitingspercentage van een tweede en 
derde ibuprofen kuur en de mogelijke bijwerkingen rapporteerde. In totaal waren er 
tussen november 2005 en september 2011 164 prematuren met een PDA opgenomen. 
Het sluitingspercentage was gelijk (X2=2.1, p=0.350) voor de eerste (66%, 109/164) , 
tweede (56%, 24/43) en derde (55%, 6/11) kuur ibuprofen. Laat starten met de eerste 
kuur ibuprofen was een voorspellende factor voor de behoefte aan een tweede kuur 
((X2=4.4, p=0.036). Er werden geen extra bijwerkingen van meerdere ibuprofenkuren 
gerapporteerd. Op basis van deze studie wordt geconcludeerd dat meerdere kuren 
ibuprofen effectief en veilig lijken. Er wordt daarom geadviseerd een tweede of derde 
ibuprofenkuur te prefereren boven mogelijk schadelijke chirurgische sluiting, indien 
een eerste of tweede ibuprofenkuur gefaald heeft.
Hoofdstuk 5 –  Gebruik van rifampicine voor persisterende 
coagulase negatieve staphylococcen sepsis bij 
neonaten.
Coagulase negatieve staphylococcen (CNS) zijn de meest voorkomende oorzaak van 
late sepsis in de Neonatale Intensive Care Unit (NICU). Slechts een klein deel van de 
neonaten reageert niet op vancomycine en ontwikkelt een persisterende bacteriemie, 
die behandeld kan worden met rifampicine (van oorsprong een antimicrobieel middel 
tegen de tuberkel bacil). In hoofdstuk 5 evalueerden we het gebruik van rifampicine 
voor persisterende CNS bacteriemie met een retrospectieve studie van 137 neonaten 
met CNS bacteriemie. Achttien van deze kinderen werden behandeld met rifampicine 
voor een persisterende CNS bacteriemie (3 positieve bloedkweken met 48 uur ertussen 
en klinische symptomen) of (een serieuze verdenking op) een intravasculaire trombus. 
De duur van de bacteriemie voor de start van rifampicine (8.0 ± 3.6 dagen) was positief 
gecorreleerd aan de totale duur van de bacteriemie (10.3 ± 3.7 dagen), dus hoe eerder 
rifampicine gestart werd, des te sneller de bloedkweek negatief werd. Na het starten van 
rifampicine daalden C-reactive protein (CRP) waarden snel en werden bloedkweken 
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negatief binnen 2.3 ± 1.6 dagen. Vancomycine spiegels werden niet structureel 
gemeten bij alle neonaten, waardoor in enkele gevallen subtherapeutische dalspiegels 
laat ontdekt werden. De resultaten van deze studie suggereren dat rifampicine effectief 
is in het behandelen van persisterende CNS bacteriemie bij neonaten, waarbij de 
uitkomst nog verbeterd kan worden door vancomycine dalspiegels goed te monitoren.
Hoofdstuk 6 –  Uitkomst en behandeling van neonatale 
thrombocytopenie als gevolg van maternale ITP 
tijdens de zwangerschap.
Ernstige neonatale trombocytopenie door maternale idiopathische trombocytopenische 
purpura is niet veel voorkomend, maar intracraniële bloedingen zijn zeer zeldzaam 
(<1%). Postnatale neonatale behandeling bestaat uit trombocytentransfusies, IVIG 
en/of prednison; maar bewijs over de postnatale behandeling van voorkeur is schaars. 
In hoofdstuk 6 rapporteerden we een retrospectieve analyse van 67 neonaten, 
geboren uit 41 moeders met ITP tijdens de zwangerschap. Ernstige neonatale 
trombocytopenie kwam voor bij 20/67 (29.9%) van de neonaten, bij één van hen 
werd unilaterale polymicrogyria waargenomen op een echo en MRI van het cerebrum. 
De ernstige trombocytopenie herstelde spontaan bij 3 neonaten; 18 neonaten werden 
behandeld met trombocytentransfusies, IVIG, prednison of combinaties daarvan 
(waarvan 1 neonaat met persisterende matige trombocytopenie). Het terugvallen van 
trombocytengetal < 50 x 109/L na trombocytentransfusies werd vaak gezien. Ernstige 
neonatale trombocytopenie in een vorige zwangerschap en een lage laagste maternale 
trombocytenwaarde tijdens de zwangerschap leken risicofactoren voor het krijgen van 
een neonaat met ernstige trombocytopenie. De resultaten van deze studie laten zien 
dat het postnatale neonatale trombocytengetal een grillig beloop kan hebben, met 
meerdere terugvallen na trombocytentransfusies. Dit suggereert dat behandeling met 
IVIG niet te lang uitgesteld moet worden en gestart dient te worden na een terugval 
na de 1e trombocytentransfusie.
Hoofdstuk 7 –  Korte en lange termijn uitkomsten van neonatale 
hyperglycemie in extreme prematuren, behandeld 
met insuline.
Hyperglycemie bij prematuren is geassocieerd met een toename in morbiditeit en 
mortaliteit, maar data over de gevolgen op lange termijn zijn beperkt. In hoofdstuk 
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7 onderzochten we de effecten van neonatale hyperglycemie (bloed glucose > 10 
mmol/l, behandeld met insuline > 12 uur) op groei, neurologische en gedragsmatige 
ontwikkeling op de leeftijd van 2 jaar in een retrospectieve follow-up studie. Tussen 
januari 2002 en december 2006 werden er 859 prematuren (< 32 weken) opgenomen, 
waarvan er 66 (8%) hyperglycemie ontwikkelden. Hyperglycemie was significant 
gerelateerd aan mortaliteit, met 27/66 (41%) in de hyperglycemische groep versus 
62/793 (8%) in de groep zonder hyperglycemie. Mortaliteit werd vooral gezien in 
hyperglycemische kinderen met gemiddelde glucosewaardes van > 8.0 mmol/L of 
maximum glucosewaardes > 9.5 mmol/L op dag 3-4 na het begin van de episode. 
Morbiditeit werd voornamelijk gezien bij kinderen met hyperglycemie én een 
geboortegewicht van < 1000 gram of amenorroeduur onder de 28 weken. 
Drieëndertig overlevende kinderen met hyperglycemie, behandeld met insuline, en 
63 controles (gematched voor amenorroeduur, geboortegewicht, geslacht en jaar van 
opname) zonder hyperglycemie werden geëvalueerd voor follow-up op de gecorrigeerde 
leeftijd van 2 jaar. Groei was vergelijkbaar, maar neurologische en gedragsmatige 
ontwikkeling waren significant vaker afwijkend bij kinderen met neonatale 
hyperglycemie in de voorgeschiedenis. We concludeerden dat, ondanks behandeling 
met insuline, hyperglycemie negatieve effecten op mortaliteit en neurologische en 
gedragsmatige ontwikkeling heeft. Meer onderzoek naar de pathofysiologie van 
hyperglycemie geïnduceerde breinschade zou waardevol zijn, naast verbetering van 
de huidige behandelingsstrategieën van neonatale hyperglycemie. 
Hoofdstuk 8 – Algemene discussie.
In de algemene discussie werden de resultaten, beschreven in dit proefschrift, voor elk 
hoofdstuk apart besproken. Er werd een samenvatting gegeven van wat al bekend is over 
elk onderwerp, waarbij de zwaktepunten, tegenstellingen en vraagtekens in de huidige 
literatuur aangestipt werden. Suggesties voor toekomstig onderzoek werden gedaan, 
voor het verbeteren van onze kennis en het optimaliseren van huidige protocollen. 
Per hoofdstuk werd een praktische toepasbare aanbeveling gedaan, gebaseerd op het 
huidige bewijs en de resultaten van de studies, beschreven in dit proefschrift. De 
algemene discussie eindigt met de boodschap dat evaluatie van beleid en aanpassing 
van protocollen voor neonaten een continue proces is, wat een toegenomen bewustzijn 
van de medische wereld en goed ontworpen studies vereist.
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List of abbreviations
 List of abbreviations
ADH Attention deficit/hyperactivity
BPD Bronchopulmonary dysplasia
BSID Bayley scales of infant development
CBCL Child behaviour checklist





DSM Diagnostic and statistical manual of mental disorder
ECG Electric cardiogram
FBS Fetal blood sampling
FNAIT Fetal- and neonatal allo-immune thrombocytopenia
GA Gestational age
HPA Human platelet antigen
ICH Intracranial haemorrhage
IgG Immunoglobulin, subclass G
ITP Idiopathic thrombocytopenic purpura
IUGR Intra uterine growth restriction
IUPT Intra uterine platelet transfusion
IVH Intraventricular haemorrhage
IVIG Intravenous immunoglobulin
MND Minor neurological dysfunction
MRI Magnetic resonance imaging
NEC Necrotizing enterocolitis
PDA Patent ductus arteriosus
PEEP Positive end expiratory pressure
PIQ Performance intelligence quotient
PROM Prolonged rupture of membranes
PVL Periventricular leukomalacia
RDS Respiratory distress syndrome.
SD Standard deviation
TIQ Total intelligence quotient
VIQ Verbal intelligence quotient
WPSSI/WISC Wechsler intelligence scale for children
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